Introduction {#s1}
============

Amyloids are ordered protein assemblies, typically rich in beta sheet, that underlie multiple disorders such as Alzheimer's disease (AD). Amyloid-forming proteins include tau, synuclein, and expanded polyglutamine proteins such as huntingtin, among many others. It is unknown how or why intracellular proteins such as tau transition from a relatively inert form to one that efficiently self-assembles into ordered structures in vivo. This process begins with the formation of a pathogenic 'seed,' a structure that serves as a template for homotypic fibril growth. This structural transition could be a critical event in the pathogenesis of neurodegeneration. Under defined conditions and relatively high concentrations (typically micromolar), recombinant tau monomer will form amyloid fibrils in vitro. However the basis of spontaneous assembly in cells is unknown. The conversion of a protein from a monomer to a large, ordered multimer could occur by several mechanisms, but the first step probably involves the formation of a seed. This event, and indeed the actual conformation or assembly state of the protein that constitutes the 'minimal' seed, has remained obscure. This has led to the idea that a seed is potentially transitory, arising from an equilibrium between two states: one relatively aggregation-resistant, and another that is short-lived. A seed could be a single molecule, or several. Based on extrapolation from kinetic aggregation studies, it has been suggested that a critical seed for tau and polyglutamine peptide amyloid formation is a single molecule ([@bib5]; [@bib2]; [@bib20]), while an earlier study (among others \[[@bib31]\]) has proposed a tau multimer ([@bib8]). Isolation of the seed-competent form of tau could be critical to understanding the initiation of disease and the design of more effective diagnostics and therapeutics.

Tau forms amyloids that underlie neurodegeneration in a variety of neuropathological syndromes, collectively termed tauopathies ([@bib24]). These include AD and frontotemporal dementias, among many others. Multiple groups, including ours, have now observed that tau will propagate an aggregated state from the outside to the inside of a cell, between cells, across synapses, and within brain networks ([@bib34]). In prior work, we used size exclusion chromatography (SEC) to define tau trimers as the minimal unit of spontaneous cellular uptake and intracellular amyloid formation, and proposed this as the smallest particle capable of propagating aggregates between cells ([@bib27]). This work involved application of 'naked' protein assemblies derived from recombinant protein or human brain onto cultured 'biosensor' HEK293 cells or primary neurons that express a tau aggregation reporter ([@bib9]; [@bib15]). Biosensor cells and primary neurons alike take up tau aggregates via macropinocytosis ([@bib14]). The aggregates subsequently serve as highly specific templates to trigger intracellular amyloid formation ([@bib15]; [@bib33]). We have also determined that preincubation of cationic lipids such as lipofectamine with tau seeds facilitates their direct transduction into a cell, bypassing the physiologic uptake mechanism ([@bib15]; [@bib11]). Lipofectamine-mediated delivery into biosensor cells allows direct quantitation of seed titer for both tau and α-synuclein ([@bib14]).

Tau is intrinsically disordered upon isolation from bacteria or mammalian cells and is relatively inert in terms of spontaneous self-assembly. However under various conditions, including exposure to polyanions such as heparin, tau will form aggregates via nucleated self-assembly ([@bib12]; [@bib30]). It is unknown how these experimental conditions relate to the initiation of aggregation in human brain. We have now purified various stable forms of full-length tau monomer from recombinant sources and human brain. One is relatively inert and is stable for long periods. Another is 'seed-competent,' triggers amyloid formation in cells and in vitro, and exhibits intrinsic properties of self-assembly. We have used crosslinking with mass spectrometry (XL-MS) to probe the structures of these molecules. Models of discrete regions within the RD predict that differential exposure of hexapeptide motifs previously known to be important for amyloid formation distinguishes the two forms of tau. These models are supported by limited proteolysis studies. The identification of distinct and stable forms of tau monomer, including some that are uniquely seed-competent, bears directly on how we understand the initiation of protein aggregation in the tauopathies.

Results {#s2}
=======

Isolation of fibril-derived monomer and other assemblies {#s2-1}
--------------------------------------------------------

We initially sought to define the tau seeding unit that would trigger intracellular aggregation upon direct delivery to the cell interior. We had previously observed that a tau trimer is the minimal assembly size that triggers endocytosis and intracellular seeding ([@bib27]). These experiments depended on spontaneous cell uptake, since no lipofectamine was added to the reactions. A prior study had also indicated the role of disulfide linkages in promoting tau aggregation, potentially by dimer formation ([@bib8]). Thus, for our initial studies we engineered and purified full-length (FL) tau monomer that lacks any internal cysteines due to alanine substitutions (C299A and C322A), termed tau (2A). FL tau (2A) cannot self-associate based on disulfide linkages, which helped prevent the formation of cryptic dimers that could have confounded our studies. These substitutions did not affect tau purification, heparin-induced fibrillization, and sonication protocols, which we performed as described previously ([@bib27]). We treated fibril preps with sonication, prior to isolation of recombinant FL tau (2A) assemblies of various sizes by size exclusion chromatography (SEC) ([@bib27]). In parallel, we also studied FL wild type (WT) tau. We purified unfibrillized recombinant FL tau (2A) monomer by SEC ([Figure 1A](#fig1){ref-type="fig"}), and isolated SEC fractions of sonicated fibrils that contained putative monomer, dimer, trimer and \~10 mer ([Figure 1B](#fig1){ref-type="fig"}).

![Seeding activity of tau monomer in cells and in vitro.\
(**A, B**) FL Cys-Tau(2A) was labeled with Alexa488 and resolved by SEC (**A**), or was fibrillized in the presence of heparin, labeled with Alexa488, sonicated, and the assemblies resolved by SEC (**B**). The column was calibrated using standards of the indicated hydrodynamic radii. Color codes indicate the putative assembly units. (**C**) Tau assemblies were seeded into tau RD-CFP/YFP biosensor cells. M~i~ represents 'inert' monomer purified in (**A**), which had no seeding activity; M~s~ represents 'seed-competent' monomer purified in (**B**), which induced intracellular tau aggregation (p\<0.001). (**D**) FL WT tau and FL Cys-Tau(2A) were similarly fibrillized, sonicated, and the fragments resolved by SEC. Seeding activity of each fraction was determined. M~s~ and larger assemblies of both forms of tau exhibited seeding activity, but not M~i~. IFD = Integrated FRET Density. (**E**) Tau assemblies of n = 1,2,3 were passed through a 100kD size cutoff filter. Filtration had no effect on the M~s~ fraction, whereas it reduced seeding of assemblies of n = 2 or 3. (**F**) Tau fibrils, trimer, or monomer were used to induce fibrillization in vitro of full-length (0N4R) tau, measured by induced thioflavin fluorescence. M~i~ had no seeding activity, whereas M~s~, trimer, and unfractionated fibrils had strong seeding activity. (**G,H**) Titration of assemblies was performed. (**G**) M~s~ exhibited an EC~50~ of approximately 10 nM (monomer equivalent); (**H**) Dimer and trimer had similar potencies. Concentration is reflected as monomer equivalent. See [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}.\
10.7554/eLife.36584.004Figure 1---source data 1.Data for M~i~ and M~s~ seeding activity in cells and in vitro.](elife-36584-fig1){#fig1}

Fibril-derived monomer exhibits seeding activity in cells and in vitro {#s2-2}
----------------------------------------------------------------------

To test the seeding activity of the tau preparations, we used a previously described 'biosensor' cell reporter line ([@bib15]). These cells stably express 4R tau repeat domain (RD) containing the disease-associated P301S mutation. All cells express 4R-RD-Cyan fluorescent protein and 4R-RD-yellow fluorescent protein (RD-CFP/YFP). Exogenously applied seeds induce intracellular aggregation with resultant fluorescence resonance energy transfer (FRET) between CFP and YFP that can be measured via flow cytometry ([@bib15]; [@bib11]). The degree of aggregation is scored using 'integrated FRET density' (IFD), which is the product of the percent positive cells and the mean fluorescence intensity of FRET-positive cells, and from this we determine a titer of tau seeding activity ([@bib15]). Lipofectamine directly transduces tau assemblies across the plasma membrane and increases the assay's sensitivity by approximately 100-fold. Upon incubation with Lipofectamine, we were surprised to observe seeding by monomer and larger assemblies alike, whether FL WT or 2A. ([Figure 1C,D](#fig1){ref-type="fig"}). Epifluorescence microscopy confirmed the presence of intracellular inclusions after FL WT tau monomer seeding ([Figure 1D](#fig1){ref-type="fig"}). We termed the inert monomer 'M~i~,' and the seed-competent monomer 'M~s~.' To rule out higher order assemblies of tau within the putative monomer fraction, immediately prior to the seeding assay we passed fractions through a 100 kDa cutoff filter to eliminate anything larger than a monomer. While monomer fraction retained \~80% of seeding activity, only \~20% of dimer seeding activity remained, and \~1--2% of trimer seeding activity remained ([Figure 1E](#fig1){ref-type="fig"}). To exclude an artifact related to Lipofectamine transduction into cells, we tested FL (2A) tau preparations in an in vitro seeding assay that induces fibril formation by full-length tau (0N4R) through iterative polymerization and agitation steps ([@bib28]). M~i~ had no intrinsic seeding activity. However M~s~ induced amyloid formation, albeit more slowly than trimer or unfractionated fibrils ([Figure 1F](#fig1){ref-type="fig"}). This slow aggregation process may reflect inefficient fibril assembly, and a predominance of small nucleated assembly events from the added monomer. We concluded that the M~s~ fraction contained seeding activity that enabled intracellular aggregation of tau RD-CFP/YFP in cells, or full-length tau in vitro. Finally, we tested whether contamination of very small amounts of seeds could somehow account for the seeding activity in monomer fractions by carrying out dose-response titrations of the various preparations. M~s~ had an EC~50~ of \~10 nM ([Figure 1G](#fig1){ref-type="fig"}), which was very similar to dimer and trimer ([Figure 1H](#fig1){ref-type="fig"}). Thus to account for signal observed in the seeding assay, contamination of an otherwise inert monomer with larger seed-competent assemblies would have to be substantial.

Comparison of M~i~ and M~s~ by CD and FCS {#s2-3}
-----------------------------------------

We tested for obvious structural differences between M~i~ and M~s~ using CD spectroscopy, which revealed none ([Figure 2A](#fig2){ref-type="fig"}). We re-tested the assemblies using fluorescence correlation spectroscopy (FCS), which measures particle diffusion through a fixed volume. As we previously observed ([@bib27]), we accurately estimated the units of small assemblies (≤10 mer), but not larger assemblies (\>10 mer) ([Figure 2B](#fig2){ref-type="fig"}). In an additional effort to detect cryptic multimers within the M~s~ preparation, we used double-label FCS. We engineered a cysteine onto the amino terminus of FL tau (2A) to enable its covalent modification (Cys-Tau (2A)). We then prepared Cys-tau (2A) fibrils, or monomer, and labeled them simultaneously with Alexa488 (green) and tetramethylrhodamine (TMR) via maleimide chemistry. We carried out sonication and purification by SEC as before, isolating assemblies of various sizes. We evaluated each for cross-correlation between red and green signal, which indicates the presence of at least two tau molecules in a particle. We analyzed \>300 events for each assembly. When we evaluated M~i~ and M~s~, 100% of events in each case showed a diffusion time consistent with a tau monomer ([Figure 2C,D](#fig2){ref-type="fig"}). Furthermore, we observed no cross-correlation between red and green signal, indicating that neither preparation had detectable multimeric assemblies ([Figure 2C,D,H](#fig2){ref-type="fig"}). By contrast, when we evaluated larger species such as dimer, trimer, or \~10 mer, we observed longer diffusion times consistent with the predicted assembly sizes, and significant cross-correlation values ([Figure 2E--H](#fig2){ref-type="fig"}), consistent with the presence of multimers. The FCS studies supported the conclusion that M~i~ and M~s~ are comprised predominantly of monomer.

![Analyses of M~i~ and M~s~ by CD and FCS.\
(**A**) CD spectra of M~i~ and M~s~ were similar. (**B**) FCS Diffusion times for M~i~, M~S~, dimer, trimer, and \~10 mer, and the cross-correlation for M~i~, M~s~, dimer, trimer, and ≥10 mer were determined after labeling of fibrils with Alexa488, or double labeling additionally with tetramethylrhodamine prior to sonication. Table reflects the predicted diffusion time and the actual diffusion time. The variance between predicted vs. observed times is reported. (**C--G**) FCS for double-labeled tau assemblies. Cross correlation (CC) between the two dyes is indicated in grey lines. (**H**) Summary of FCS cross-correlation, including free dyes. Neither free dye, M~i~ nor M~s~ showed any cross-correlation, indicating that single species predominate. All multimeric assemblies exhibited cross-correlation, indicating detection of both dyes within a single particle. See [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}.\
10.7554/eLife.36584.006Figure 2---source data 1.Data for CD and FCS of M~i~ and M~s~.](elife-36584-fig2){#fig2}

SEC preparation efficiently purifies M~s~ monomer {#s2-4}
-------------------------------------------------

To rule out cross-contamination of assemblies within the SEC column, we tested its ability to exclude larger seeds from the monomer fraction. We first isolated M~s~ and larger assemblies from a sonicated fibril preparation ([Figure 3](#fig3){ref-type="fig"}, Group 1). Removing the fraction that contained M~s~ (B5), we then pooled the remaining fractions, and spiked them with M~i~. We re-fractionated the material on SEC to isolate the monomer in fraction B5 again ([Figure 3](#fig3){ref-type="fig"}, Group 2). As previously observed, M~s~ and other fibril-derived assemblies in Group 1 had seeding activity ([Figure 3](#fig3){ref-type="fig"}). However, in Group 2, while we observed seeding activity in larger assemblies, the monomer (which we take to be M~i~) re-isolated from a pool of larger fibril-derived assemblies had no seeding activity ([Figure 3](#fig3){ref-type="fig"}). This confirmed that larger, seed-competent assemblies do not appreciably contaminate the monomer fraction during SEC.

![Fidelity of SEC purification of assemblies.\
SEC fidelity was tested by isolating M~s~ from fractions after fibril sonication. Remaining fractions were combined with M~i~, and the mix was re-isolated by SEC. In Group 1, after the first isolation, the monomer fraction (which contains M~s~) contained seeding activity. In Group 2, after the second purification by SEC, the monomer fraction (which contains M~i~ spiked in) did not exhibit seeding activity. See [Figure 3---source data 1](#fig3sdata1){ref-type="supplementary-material"}.\
10.7554/eLife.36584.008Figure 3---source data 1.Data for fidelity of SEC purification of assemblies.](elife-36584-fig3){#fig3}

Heat denaturation of assemblies {#s2-5}
-------------------------------

Although prior controls had essentially excluded the presence of tau multimers in the sample, we used heat-mediated dissociation of oligomeric assemblies as an additional test for the possibility that M~s~ in fact represents a uniquely compact multimer that somehow purifies as a monomer. We collected M~s~ by SEC, and heated the sample to 95°C for 3 hr. We then re-isolated the sample via SEC. We carried out the same procedure with trimer and \~20 mer. In each case, we tested the resultant fractions for seeding activity. In the first instance, after heating we re-isolated M~s~ purely as monomer that retained virtually all of its seeding activity ([Figure 4A](#fig4){ref-type="fig"}). The trimer assembly (fraction B8) broke down to smaller assemblies, predominantly monomer, each of which retained seeding activity ([Figure 4B](#fig4){ref-type="fig"}). The \~20 mer (fraction A5) was largely stable following heat treatment, and retained its seeding activity ([Figure 4C](#fig4){ref-type="fig"}). These experiments highlighted the lability of small multimers (i.e. trimer), and a surprising persistence of seeding activity in heat-treated monomer.

![Heat denaturation of assemblies.\
(**A--C**) Heat-induced dissociation of assemblies. (**A**) The SEC fraction containing M~s~ (**B5**) was heated to 95°C for 3 hr and re-isolated by SEC prior to testing the FRET biosensor assay. No loss in seeding activity was observed. (**B**) When the SEC fraction containing trimer (**B8**) was heated similarly, seeding activity shifted to fractions that contain dimer and monomer (**B7, B5**). (**C**) \~ 20 mer (**A5**) was largely stable to heating, although some smaller seed-competent assemblies were liberated. (**D--G**) Various assemblies were subjected to heat denaturation at the indicated temperatures and times, followed by analysis of seeding activity in the FRET biosensor assay. Whereas \~10 mer and \~20 mer were relatively stable from 65--95°C, monomer, dimer and trimer showed temperature-dependent loss of seeding activity. (**H**) Plot of denaturation data for M~s~ with multimodal regression curves superimposed. See [Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"}.\
10.7554/eLife.36584.010Figure 4---source data 1.Data for heat denaturation of assemblies.](elife-36584-fig4){#fig4}

Differential heat lability of tau assemblies {#s2-6}
--------------------------------------------

In the preceding experiment M~s~ retained seeding activity even after 3 hr at 95°C, a condition sufficient to dissociate trimers. These experiments implied that M~s~ consists of a stable seed-competent structure, resistant to heat denaturation. Consequently, we used more nuanced heat denaturation of seeding activity to probe the relative stabilities of M~s~, dimer, trimer, and larger assemblies of FL WT tau. We first isolated tau monomer, dimer, trimer,\~10 mer, and \~20 mer on SEC. We then incubated the various assemblies at a range of temperatures (65, 75, 85, 95°C) and times (0, 3, 12, 18, 24, 48, 72 hr) before measuring seeding activity. Lower temperatures only slightly reduced seeding activity, whereas exposure of M~s~, dimer, and trimer to temperatures ≥ 85°C for 18--24 hr eliminated it at roughly the same rate for each ([Figure 4D--G](#fig4){ref-type="fig"}). By contrast, the seeding activities of \~10 mer and \~20 mer were relatively heat-resistant ([Figure 4D--G](#fig4){ref-type="fig"}). This was consistent with our prior observations that tau seeds derived from cultured cells are resistant to boiling ([@bib33]). To determine a putative energy barrier between M~s~ and M~i~, we evaluated the denaturation data for M~s~ by integrating the data from the prior experiments ([Figure 4H](#fig4){ref-type="fig"}). We compared two models for the transition of M~s~ to an inert form (which we assumed to be an unfolding reaction): a unimodal unfolding model vs. a multimodal model that assumes intermediate seed-competent states. The unimodal model did not account for the data at early time points, which indicated a lag phase in denaturation, whereas the multimodel model performed better ([Figure 4H](#fig4){ref-type="fig"}). The lag phase in denaturation implied an ensemble of seed-competent states that define M~s~, each separated by smaller energy barriers. Using the multimodal model, we calculated the barrier to conversion of M~s~ to an inert form to be \~78 kcal/mol.

M~s~ has unique properties of self-assembly {#s2-7}
-------------------------------------------

Aggregation of M~i ~in vitro is relatively slow, requires high protein concentration (micromolar), and polyanions such as heparin ([@bib12]; [@bib30]). Based on the seeding activity of M~s~, we predicted that it might more readily self-associate. We incubated FL WT tau M~i~ and M~s~ alone, or dimer or trimer at equimolar ratios, keeping total particle concentration constant at 500 nM. We then monitored change in assembly size over 24 hr. M~i~, dimer, and trimer showed no evidence of self-association in this timeframe ([Figure 5A,C,D](#fig5){ref-type="fig"}). By contrast, when incubated alone, M~s~ readily formed larger assemblies ([Figure 5B](#fig5){ref-type="fig"}). When we incubated M~i~ with dimer or trimer, we saw no change in the assembly population over 24 hr ([Figure 5E,F](#fig5){ref-type="fig"}). By contrast, when we mixed M~s~ with dimer or trimer we observed a growth of larger assemblies with a concomitant reduction in dimer and trimer peaks ([Figure 5G,H](#fig5){ref-type="fig"}). We conclude that M~i~, dimer, and trimer do not form larger assemblies at an appreciable rate, while M~s~ self-assembles and adds on to larger assemblies.

![M~s~ self-assembles.\
M~i~ and M~s~ were incubated at 500 nM or with equivalent amounts (monomer equivalent) of dimer and trimer for various times prior to resolution by SEC. Assemblies were monitored by reading the absorbance of fractions using micro BCA assay. (**A**) M~i~ showed no self-association. (**B**) M~s~ exhibited self-association over time. (**C,D**) Dimer and trimer were stable over time. (**E,F**) M~i~ does not react with dimer or trimer to form larger assemblies. (**G,H**) M~s~ reacts with dimer and trimer to form larger assemblies. See [Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}.\
10.7554/eLife.36584.012Figure 5---source data 1.Data for M~s~ self-assembly.](elife-36584-fig5){#fig5}

Heparin induces transition from M~i~ to M~s~ {#s2-8}
--------------------------------------------

The preparation of M~s~ based on sonication of fibrils raised two important issues. First, it left uncertain whether M~i~ could be converted to a seed-competent form without previously being incorporated into a fibril. Second, we observed that sonication could create fragments from tau monomer that might potentially act as seeds ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). Consequently, we used heparin to induce the formation of M~s~, thereby avoiding sonication. We exposed FL WT tau to heparin for varying amounts of time before purifying different assembly sizes by SEC and testing for seeding activity. After 15 min of heparin exposure, we detected low but significant amounts of seed-competent monomer, and much fewer larger assemblies ([Figure 6A](#fig6){ref-type="fig"}). Crosslinking of purified, heparin-induced M~s~ revealed no evidence of multimers or an increase in fragments ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). Recombinant monomer not treated with heparin had no seeding activity at any time point ([Figure 6A](#fig6){ref-type="fig"}). At longer heparin treatment times (1 hr, 4 hr) monomer fractions as well as larger assemblies all had strong seeding activity ([Figure 6A](#fig6){ref-type="fig"}). M~s~ derived from heparin exposure was relatively resistant to heat denaturation at 95°C, albeit less so than fibril-derived M~s~ ([Figure 6B](#fig6){ref-type="fig"}). Relative seeding efficiency of the various forms of M~s~ as well as sonicated or unsonicated fibrils were relatively similar ([Figure 6C](#fig6){ref-type="fig"}). We noted also that sonication of M~i~ and purification by SEC did not produce any seed-competent species, eliminating the possibility that small assemblies of sonication-induced fragments accounted for seeding activity of M~s~ ([Figure 6C](#fig6){ref-type="fig"}). These experiments also indicated that it is not necessary for tau monomer to be part of a fibril or to be exposed to sonication to produce an efficient seed-competent monomer. Heparin, presumably by catalyzing a transition from an inert to a seed-competent form, enables this critical conformational change.

![Heparin induces transition from M~i~ to M~s~.\
(**A**) Heparin treatment of FL WT tau was carried out for 15 min, 1 hr, or 4 hr. Samples were resolved by SEC, and fractions of various sizes were compared using the biosensor seeding assay. 'Pre-SEC' refers to the sample prior to fractionation. NT = monomer not treated with heparin. At 15 min, a small, but significant seeding activity was observed primarily in the monomer fraction. By 1 hr this signal was very strong, and comparable to the signal of M~s~ derived from sonicated fibrils. (**B**) M~s~ derived from 4 hr heparin exposure was heated at 95°C for different times, followed by analysis of seeding activity in the FRET biosensor assay. Seeding activity decayed over 24 hr. (**C**) Seeding efficiencies per nM of tau (monomer equivalent) of the various forms of M~s~, sonicated, or unsonicated fibrils were relatively similar. M~i~ was sonicated identically to M~s~, followed by purification via SEC, but exhibited no seeding activity. Transfection of heparin failed to trigger intracellular aggregation (data not shown). See [Figure 6---source data 1](#fig6sdata1){ref-type="supplementary-material"}.\
10.7554/eLife.36584.015Figure 6---source data 1.Data for heparin induced transition from M~i~ to M~s~.](elife-36584-fig6){#fig6}

XL-MS reveals unique contacts associated with M~s~ {#s2-9}
--------------------------------------------------

To probe the structures of M~i~ and M~s~, we employed cross-linking with mass spectrometry (XL-MS), which uses DSS-mediated crosslinking of proteins (monomer or larger assembly) followed by trypsin proteolysis, enrichment of resultant fragments by SEC, and identification by capillary liquid chromatography tandem mass spectrometry. This method creates restraints for structural models of single proteins or protein complexes ([@bib25]; [@bib23]; [@bib17]). We assigned the complex fragment ion spectra to the corresponding peptide sequences using xQuest ([@bib32]). Denaturation of recombinant tau with 8M urea prior to crosslinking produced no intramolecular cross-links (data not shown), indicating that crosslinks observed under native conditions represented local structure. We studied M~i~, fibril-derived M~s~ and heparin-derived M~s~ using XL-MS. Short reaction times ensured the production of only intra-molecular crosslinks as monitored by SDS-PAGE ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). XL-MS for each sample was carried out in triplicate , and only considering consensus crosslinks present in each replicate . M~i~ exhibited crosslink patterns which indicated local and distant intramolecular contacts ([Figure 7A](#fig7){ref-type="fig"}). In M~s~, we observed a consistent crosslinking of K150 with K254, K267, K274 or K280 all located between RD 1 and 2. These crosslinks tracked exclusively with M~s~, both fibril- or heparin-derived ([Figure 7B,C](#fig7){ref-type="fig"}). We never observed these crosslinks in M~i~. To test the relationship of this crosslink with seed function, we carried out heat denaturation at 95°C for 3 or 24 hr, followed by XL-MS. Heating samples results in a decrease in crosslink frequency ([Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}). Importantly, however, we observed a parallel persistence of this crosslink pattern with seeding activity ([Figure 7B,C](#fig7){ref-type="fig"}). The XL-MS results indicate a distinct structure and seeding activity for M~s~ that is surprisingly resistant to denaturation at 95°C.

![Unique XL-MS patterns for different forms of M~i~ and M~s~.\
Tau monomers were prepared as described, heated at 95°C for 0, 3 or 24 hr, reacted with DSS, proteolyzed and analyzed by mass spectrometry to define intramolecular crosslinks. Diagrams represent crosslinks within the tau protein. Tau is shown in grey; RD is colored in red (**R1**), green (**R2**), blue (**R3**) and indigo (**R4**). Each diagram indicates consensus crosslinks present across replicates (N = 3) (green or red). Crosslinks uniquely observed within M~s~ preparations are shown in red. Each sample was prepared, isolated by SEC, and then subjected XL-MS. (**A**) M~i~: tau monomer not previously fibrillized; (**B**) M~s~: fibril-derived tau monomer; (**C**) M~s~: heparin-exposed tau monomer (0.25 hr or 1 hr). Crosslinks from aa150 to aa254-290 mark all forms of M~s~ after exposure to 95°C for 0 hr, 0.25 hr and 3 hr, but not 24 hr. See [Figure 7---source data 1](#fig7sdata1){ref-type="supplementary-material"} and [2](#fig7sdata2){ref-type="supplementary-material"}.\
10.7554/eLife.36584.018Figure 7---source data 1.Summary of triplicate XL-MS datasets.\
10.7554/eLife.36584.019Figure 7---source data 2.Summary of consensus XL-MS datasets.](elife-36584-fig7){#fig7}

AD brain contains M~s~ {#s2-10}
----------------------

Given our experiments with recombinant M~i~ and M~s~, we wished to test whether similar structures exist in vivo. We extracted AD and control brain samples using a dounce homogenizer to avoid liberating significant monomer from fibrils. We immunoprecipitated tau using an antibody that targets the amino-terminus (HJ8.5), and resolved the eluates by SEC, followed by ELISA to determine tau levels ([Figure 8A,B](#fig8){ref-type="fig"}). Tau from control brain purified in the monomer fraction ([Figure 8A](#fig8){ref-type="fig"}), while tau from AD brain distributed across multiple fractions, corresponding to monomer and larger assemblies ([Figure 8B](#fig8){ref-type="fig"}). When we tested each fraction for seeding activity, we observed none in any control brain fraction ([Figure 8C](#fig8){ref-type="fig"}). However, all AD fractions contained seeding activity, including monomer ([Figure 8C](#fig8){ref-type="fig"}). To exclude the possibility that the brain homogenization protocol liberated M~s~ from neurofibrillary tangles, we spiked tau KO mouse brain samples with recombinant fibrils in vitro, or fibril-derived M~s~. We then used dounce homogenization and immuno-purification as for human brain. We evaluated the seeding activity in total lysate, supernatant following 10,000 x g centrifugation, and SEC fractions ([Figure 8D](#fig8){ref-type="fig"}). We readily observed monomer seeding activity in tau KO brain spiked with M~s~, however we observed none in fractions that had been spiked with fibrils ([Figure 8D](#fig8){ref-type="fig"}). The homogenization protocol for human brain was thus unlikely to have liberated M~s~ from pre-existing tau fibrils.

![AD brain contains seed-competent monomer.\
Tau from control and AD brains was immunoprecipitated and subjected to SEC. (**A**) SEC from control brain contained predominantly tau monomer. (**B**) SEC from AD brain contained a range of tau assembly sizes. (**C**) Tau monomer from control brain exhibited no seeding activity, whereas monomer from AD brain did, along with larger assemblies (p\<0.001). Tau Unit refers to the putative number of molecules per assembly. LF = Lipofectamine control. (**D**) Tau KO mouse brain was spiked either with human tau M~s~ or fibrils prior to dounce homogenization, immunopurification, and resolution by SEC. Samples spiked with M~s~ exhibited monomer seeding activity, but not samples that had been spiked with fibrils. (**E**) AD-derived tau monomer was incubated for the indicated times prior to SEC and determination of seeding activity in each fraction. Larger seed-competent assemblies formed after 24 hr incubation at RT. (**F, G**) Three control and AD brains were homogenized, monomer isolated, and evaluated by XL-MS. Tau monomer from controls lacked the long-range crosslinks observed in M~s~. AD-derived M~s~ contained long-range crosslinks (aa150 to aa254-290) also observed in recombinant forms of M~s~. See [Figure 8---source datas 1](#fig8sdata1){ref-type="supplementary-material"} and [2](#fig8sdata2){ref-type="supplementary-material"}.\
10.7554/eLife.36584.022Figure 8---source data 1.Data characterization of patient samples.\
10.7554/eLife.36584.023Figure 8---source data 2.Summary of patient-derived XL-MS datasets.](elife-36584-fig8){#fig8}

To test for self-association of control-derived M~i~ vs. AD-derived M~s~, we purified these species by SEC, and divided each monomer fraction in two. We snap-froze one fraction and incubated the other overnight at room temperature. Then, we again resolved the assemblies via SEC and tested each fraction for seeding activity. Control monomer was inert, even after incubation at RT ([Figure 8E](#fig8){ref-type="fig"}). AD-derived M~s~ that was purified, frozen, and re-purified by SEC exhibited seeding activity exclusively in the monomer fraction ([Figure 8E](#fig8){ref-type="fig"}). By contrast, AD-derived M~s~ incubated at RT formed seed-competent assemblies of increasing size ([Figure 8E](#fig8){ref-type="fig"}). We concluded that, as for other types of M~s~, AD-derived M~s~ exhibited an intrinsic capacity for self-association into seed-competent assemblies. To compare structures of control vs. AD-derived monomer via XL-MS, we isolated tau from brains of 3 AD patients and three age-matched controls. In control-derived monomer, we observed no evidence of the crosslink that marked M~s~ ([Figure 8G](#fig8){ref-type="fig"}). However, in each AD-derived M~s~ sample we observed a discrete set of crosslinks between aa150 and aa259-290 ([Figure 8H](#fig8){ref-type="fig"}). This essential finding did not change, no matter what method of homogenization we used ([Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}), and implied a common structure that unifies ensembles of seed-competent tau monomer, whether produced in vitro or in vivo.

Models of seed-competent monomer suggest exposure of VQIINK and VQIVYK {#s2-11}
----------------------------------------------------------------------

Based on intramolecular FRET and electron paramagnetic resonance spin labeling Mandelkow et al. have previously proposed native tau structure to be in a 'paperclip' configuration, with the C-terminus folded over the RD ([@bib16]). To understand how core elements of tau control its aggregation, we employed Rosetta to create models of tau structure for M~i~ and M~s~ using restraints from the crosslink patterns and length of the DSS crosslinker. The overall energetics and radii of gyration in the models were comparable for M~i~ and M~s~ ([Figure 9---figure supplement 1](#fig9s1){ref-type="fig"}), indicating global structural similarity. We thus focused on the RD, given its high frequency of intramolecular crosslinks, and primary role in aggregation ([Figure 9A](#fig9){ref-type="fig"}). We observed differences in the predicted interface structure between R1/R2 and R2/R3 which encode two core VQIINK and VQIVYK motifs critical for tau amyloid formation ([@bib36]; [@bib35]). The M~i~ structural model predicted masking of VQIINK and VQIVYK sequences in compact 'hairpin' structures ([Figure 9B](#fig9){ref-type="fig"}), similar to the structure of microtubule-bound tau previously determined by NMR ([@bib18]). By contrast, within M~s~ the model predicted relative exposure of VQIINK and VQIVYK ([Figure 9C](#fig9){ref-type="fig"}). We next evaluated XL-MS-guided predictions of patient-derived tau, although lower sample quality and fewer high confidence crosslinks (possibly due to protein heterogeneity) limited our accuracy. As for recombinant protein, M~i~ from control patients also featured VQIINK/VQIVYK sequences in a less accessible configuration ([Figure 9D](#fig9){ref-type="fig"}). In AD-derived M~s~, long-range contacts from aa150 to R2 influenced the model, and predicted an exposed configuration of VQIINK/VQIVYK ([Figure 9E](#fig9){ref-type="fig"}). With important caveats, the models guided by XL-MS imply that the general difference between M~i~ and M~s~ derives from relative shielding vs. exposure of VQIINK/VQIVYK sequences.

![Models of M~i~ and M~s~ suggest differences in the R1R2 and R2R3 regions.\
XL-MS identified pairs were used as restraints in Rosetta to create structural models of discrete tau domains. (**A**) Schematic highlighting the region of the RD encoding structural differences between M~i~ and M~s~. Tau RD is colored in red (**R1**), green (**R2**), blue (**R3**) and indigo (**R4**); N- and C-terminal portions of tau are shown in grey. Fragments of interest are shown with their position in the RD. (**B**) recombinant M~i~; (**C**) fibril-derived M~s~, (**D**) Control M~i~ and (**E**) AD-derived M~s~. Regions surrounding the R1R2 and R2R3 are indicated, highlighting two amyloid-forming sequences, VQIINK (green spheres) and VQIVYK (blue spheres). In both forms of M~i~ VQIINK and VQIVYK are associated with flanking amino acids in hairpin structures. In both forms of M~s~ the VQIINK and VQIVYK sequences are presented at the protein surface. See [Figure 9---source data 1](#fig9sdata1){ref-type="supplementary-material"}.\
10.7554/eLife.36584.026Figure 9---source data 1.Models of M~i~, M~s~, control and AD conformations of tau.\
10.7554/eLife.36584.027Figure 9---source data 2.Rosetta energy and radius of gyration for structural ensembles.](elife-36584-fig9){#fig9}

Limited proteolysis supports models of exposed VQIINK/VQIVYK sequences {#s2-12}
----------------------------------------------------------------------

As an orthogonal comparison of the structures of M~i~ and M~s~, we used limited proteolysis with trypsin. M~i~ or M~s~ (heparin-exposed) that had been passed through a 100kD filter immediately prior were subjected to a fine time course of limited proteolysis ([Figure 10A](#fig10){ref-type="fig"}). Each sample was prepared in triplicate with matched protein quantities to facilitate label-free analysis. We then used mass spectrometry to evaluate the production of tau fragments and mapped these to specific cleavage sites ([Figure 10B](#fig10){ref-type="fig"}). We identified 60 peptides common across the two conditions ([Figure 10---figure supplement 1](#fig10s1){ref-type="fig"}). To summarize enrichment of peptides across the two datasets we compared the ratio of averaged kinetic profiles ([Figure 10---figure supplement 1](#fig10s1){ref-type="fig"}). Differences between the M~i~ and M~s~ primarily localized to the RD ([Figure 10---figure supplement 1](#fig10s1){ref-type="fig"}). In M~i~, an R1R2 fragment was enriched ([Figure 10C](#fig10){ref-type="fig"}) while only the R2 portion of that fragment was enriched in M~s~ ([Figure 10D](#fig10){ref-type="fig"}). We observed similar patterns in R2R3 ([Figure 10F,G](#fig10){ref-type="fig"}). By contrast, other domains outside of these regions had similar cleavage kinetics in M~i~ and M~s~ ([Figure 10E,H](#fig10){ref-type="fig"}, [Figure 10---figure supplement 1](#fig10s1){ref-type="fig"}). Mapping these cleavage sites onto our structural models revealed that proteolysis in M~i~ preferentially occurred outside the hairpin that includes VQIINK and VQIVYK amyloid sequences, while cleavage in M~s~ occurred adjacent to the amyloid sequences ([Figure 10I,J](#fig10){ref-type="fig"}). The cleavage patterns were thus consistent with structural models of VQIINK and VQIVYK regions, which predicted relative inaccessibility of hairpin-associated sequences in M~i~, and accessibility in M~s~.

![Proteolysis of M~i~ and M~s~ reveals distinct patterns.\
(**A**) M~i~ and M~s~ were prepared as technical triplicates (N = 3), isolated by SEC, and passed through a 100kD filter immediately prior to exposure to trypsin for 1, 5, 10, 30, 60 and 120 min. Samples were analyzed by mass spectrometry and kinetic profiles were generated for peptides present at each time point. (**B**) Tau RD is colored in red (**R1**), green (**R2**), blue (**R3**) and indigo (**R4**). Identified peptides are shown with their position in the RD. (**C--H**) Kinetic profiles are indicated for peptides that were more abundant in M~i~ (**C, F**), M~s~ (**D, G**) or equal in M~i~ and M~s~ (**E, H**). M~i~ and M~s~ kinetic profiles are shown in blue and black, respectively. Fragments enriched in M~i~ or M~s~ were mapped onto corresponding regions in the structural models (**I, J**). The models are shown as cartoons colored in red (**R1**), green (**R2**) and blue (**R3**). Cleavage sites are indicated by arrows for M~i~ (blue) and M~s~ (black). See [Figure 10---source data 1](#fig10sdata1){ref-type="supplementary-material"}.\
10.7554/eLife.36584.030Figure 10---source data 1.Summary of peptides and their abundance identified in the triplicate M~i~ and M~s~ proteolysis experiment.\
10.7554/eLife.36584.031Figure 10---source data 2.Summary of ratiometric analysis of M~i~ and M~s~ peptide abundance.](elife-36584-fig10){#fig10}

Discussion {#s3}
==========

We propose that tau monomer occupies two distinct and stable conformational ensembles. One set of structures (collectively termed M~i~) is relatively inert, while another has intrinsic ability to self-assemble, and acts as a template, or seed, for fibril growth in vitro and in cells (collectively termed M~s~). Multiple controls indicated that our original preparation of fibril-derived M~s~ is in fact a monomer, uncontaminated by larger assemblies. Tau monomer purified from AD brain also had intrinsic seeding activity, and self-associated to produce larger seed-competent assemblies. A model restrained by the XL-MS data, and consistent with biochemical studies, predicts that VQIVYK and VQIINK sequences assume an open configuration in all types of M~s~ (fibril-derived, heparin-induced, and AD-derived). By contrast, the model predicts lack of VQIINK/VQIVYK exposure in M~i~. Limited proteolysis studies are consistent with this idea, although clearly more detailed biochemical, biophysical, and structural analyses will be needed to test its validity. Taken together, these data establish a new concept for tau: this intrinsically disordered protein has multiple, stable monomeric states, functionally distinguished by the presence or absence of seeding activity.

Amyloid proteins form progressively larger assemblies over time, and it has been difficult to define the composition of the minimal seed. Mandelkow and colleagues studied tau aggregation in vitro and concluded that a seed of 8--12 molecules existed in their experimental system ([@bib8]). By contrast, Kuret and colleagues posited an 'intermediate' of tau that could subsequently initiate self-assembly, and their data, based on extrapolation of tau concentrations needed to enable development of thioflavin fluorescence in vitro, were consistent with a monomeric seed ([@bib5]). Wetzel and colleagues also proposed that a monomer is the basis of a 'thermodynamic nucleus' that templates the aggregation of synthetic polyglutamine peptides ([@bib2]). However, no prior study has previously identified stable forms of tau monomer that seed amyloid formation.

The actual cause of tau aggregation in tauopathies is unknown. It has been proposed that dissociation of tau monomer from microtubules, possibly due to phosphorylation, allows high concentration and self-association to form pathogenic assemblies ([@bib26]). In this study, using a single source of recombinant protein, we define distinctly structured seed-competent and inert forms of tau. We have similarly identified seed-competent species in human brain. In reality 'seed-competent' and 'inert' forms of tau almost certainly represent multiple structural ensembles separated by defined energy and/or kinetic barriers. The barrier for conversion of an inert to a seed-competent form of tau can apparently be overcome by incubation with heparin and/or incorporation into a fibril. In neurons, other factors such as post-translational modifications and heterologous binding events likely play a role. Identification of the factors that trigger conversion from inert to seed-competent forms will thus have obvious implications for understanding disease mechanisms.

Isolation of seed-competent monomer from AD brain, with a very mild purification that explicitly excludes sonication or vigorous tissue homogenization, strongly suggests that this form of tau exists in vivo. Furthermore, we observed that both recombinant M~s~ and AD-derived M~s~ build multimeric assemblies in vitro far more efficiently than M~i~ or control-derived monomer. Thus, we hypothesize that a uniquely structured form of tau may be required for efficient assembly growth in cells. This contrasts with the idea that multimeric assemblies uniquely stabilize the conformation of otherwise unstructured proteins as they incorporate into the growing fibril, or that liquid-liquid phase separation with extremely high local concentration underlies tau aggregation ([@bib37]). Instead, we imagine that the initiation of aggregation in human brain might begin with a stable transition of tau monomer from an inert to a seed-competent form. To fully study this process will require more extensive biochemical purification of tau M~s~ from the earliest stages of disease.

M~s~ has a remarkably stable structure, as it resists heat denaturation at 95°C for up to 3 hr. This suggests a heretofore unrecognized conformation of tau that, to account for its slow denaturation, likely involves multiple intra-molecular interactions involving short and long range amino acid contacts. XL-MS provides some indication of what these might be, and crosslinks between aa150 and R1/R2 appear to mark a seed-competent conformation. In agreement with the XL-MS results, we observed that heat inactivation of M~s~ seeding activity occurs with a lag phase, rather than first order time-dependent decay. This implies a complex tertiary structure in which M~s~ has multiple seed-competent intermediates. Future XL-MS studies performed at different temperatures could reveal these structures. With more advanced methods to interrogate the structure of monomeric tau in patient material, we imagine that 'seed-competent monomer' will in fact represent myriad structures, depending on the underlying disease. This could provide an explanation for how a single tau protein might self-assemble into diverse amyloid strains. We note with excitement a recent study of the yeast prion Sup35 from the Tanaka laboratory. Like tau, Sup35 is intrinsically disordered, yet they have observed local structure that influences the conformations of fibrils it can form ([@bib29]).

Without further studies to identify structures of tau at higher resolution, we cannot know for certain why one form acts as a seed and another does not. However, we gained important insights when we modeled the configurations of R1R2 and R2R3 using Rosetta, with crosslinks as restraints. With obvious caveats, our models predicted that the local environment surrounding two hexapeptide motifs, VQIINK and VQIVYK, which are required for tau to form amyloid structures, may explain the differences between seed-competent and inert forms. In the models of M~i~, and control brain-derived tau, these motifs lie buried in hairpin structures. By contrast, in M~s~ and AD-derived tau, both are exposed. VQIINK and VQIVYK thus might mediate intermolecular interaction in a growing assembly. In support of our structural model, the proteolysis experiments corroborate differences in exposure of the VQIINK and VQIVYK sequences in the R1R2 and R2R3 regions between M~i~ and M~s~. We note with great enthusiasm the recent study of Fitzpatrick et al. ([@bib7]), which defined critical sequences of tau within the amyloid core that are based on VQIVYK and adjacent amino acids. Indeed, it has been recently observed that heparin binding involves residues spanning 270--290, and promotes expansion of the remainder of the molecule ([@bib39]). This is consistent with our predictions of relative exposure of VQIINK/VQIVYK. The diversity of exposed core elements (almost certainly beyond VQIINK/VQIVYK) could specify the formation of assemblies that give rise to distinct strains, as suggested by work from the Tanaka laboratory ([@bib29]). Consistent with this idea, the Fitzpatrick et al. study indicates that in AD-derived tau fibrils the VQIVYK sequence plays a key role in the core amyloid structure (along with adjacent amino acids), but the VQIINK sequence does not ([@bib7]). We also note that multiple disease-associated mutations in tau affect residues in close proximity to VQIINK/VQIVYK. For example, our models predict that serine or leucine substitutions at P301 (which cause dominantly inherited tauopathy) would uniquely destabilize the local structure and promote exposure of the VQIINK/VQIVYK sequences. Future experiments will test these ideas more definitively.

Materials and methods {#s4}
=====================

  ------------------------------------------------------------------------------------------------------------------------------------
  Reagent type (species)\   Designation                     Source or reference         Identifiers           Additional information
  or resource                                                                                                 
  ------------------------- ------------------------------- --------------------------- --------------------- ------------------------
  Cell line\                Tau RD P301S FRET\              Produced by Diamond\        ATCC CRL-3275         
  (HEK293)                  Biosensor                       lab, also available from\                         
                                                            ATCC                                              

  biological\               Tau KO mouse                    Jackson Laboratories        7251                  
  sample (mouse)                                                                                              

  biological\               Alzheimer\'s Disease\           Washington University\      62579, 62732, 61473   
  sample (human)            brain, stage VI, frozen         in St. Louis                                      

  biological sample\        Human normal brain              Washington University\      60974, 607, 64238     
  (human)                                                   in St. Louis                                      

  antibody                  HJ8.5                           Produced by Diamond lab     N/A                   Monoclonal antibody\
                                                                                                              against human tau

  antibody                  Polyclonal Rabbit\              Dako, Denmark               A0024                 
                            Anti-Human Tau                                                                    

  antibody                  ECL Anti-rabbit IgG\            GE Healthcare               NA9340V               
                            Horseradish Peroxidase F(ab)\                                                     
                            fragment                                                                          

  recombinant protein       Human tau 2N4R\                 Produced by Diamond lab     N/A                   MAEPRQEFEV\
                            (Full Length WT-tau)                                                              MEDHAGTYGL\
                                                                                                              GDRKDQGGYT\
                                                                                                              MHQDQEGDTD\
                                                                                                              AGLKESPLQT\
                                                                                                              PTEDGSEEPG\
                                                                                                              SETSDAKSTP\
                                                                                                              TAEDVTAPLV\
                                                                                                              DEGAPGKQAA\
                                                                                                              AQPHTEIPEG\
                                                                                                              TTAEEAGIGD\
                                                                                                              TPSLEDEAAG\
                                                                                                              HVTQARMVSK\
                                                                                                              SKDGTGSDDK\
                                                                                                              KAKGADGKTK\
                                                                                                              IATPRGAAPP\
                                                                                                              GQKGQANATR\
                                                                                                              IPAKTPPAPK\
                                                                                                              TPPSSGEPPK\
                                                                                                              SGDRSGYSSP\
                                                                                                              GSPGTPGSRS\
                                                                                                              RTPSLPTPPT\
                                                                                                              REPKKVAVVR\
                                                                                                              TPPKSPSSAK\
                                                                                                              SRLQTAPVPM\
                                                                                                              PDLKNVKSKI\
                                                                                                              GSTENLKHQP\
                                                                                                              GGGKVQIINK\
                                                                                                              KLDLSNVQSK\
                                                                                                              CGSKDNIKHV\
                                                                                                              PGGGSVQIVY\
                                                                                                              KPVDLSKVTS\
                                                                                                              KCGSLGNIHH\
                                                                                                              KPGGGQVEVK\
                                                                                                              SEKLDFKDRV\
                                                                                                              QSKIGSLDNI\
                                                                                                              THVPGGGNKK\
                                                                                                              IETHKLTFRE\
                                                                                                              NAKAKTDHGA\
                                                                                                              EIVYKSPVVS\
                                                                                                              GDTSPRHLSN\
                                                                                                              VSSTGSIDMV\
                                                                                                              DSPQLATLAD\
                                                                                                              EVSASLAKQG L

  recombinant protein       Tau (2A)                        Produced by Diamond lab     N/A                   MAEPRQEFEV\
                                                                                                              MEDHAGTYGL\
                                                                                                              GDRKDQGGYT\
                                                                                                              MHQDQEGDTD\
                                                                                                              AGLKESPLQT\
                                                                                                              PTEDGSEEPG\
                                                                                                              SETSDAKSTP\
                                                                                                              TAEDVTAPLV\
                                                                                                              DEGAPGKQAA\
                                                                                                              AQPHTEIPEG\
                                                                                                              TTAEEAGIGD\
                                                                                                              TPSLEDEAAG\
                                                                                                              HVTQARMVSK\
                                                                                                              SKDGTGSDDK\
                                                                                                              KAKGADGKTK\
                                                                                                              IATPRGAAPP\
                                                                                                              GQKGQANATR\
                                                                                                              IPAKTPPAPK\
                                                                                                              TPPSSGEPPK\
                                                                                                              SGDRSGYSSP\
                                                                                                              GSPGTPGSRS\
                                                                                                              RTPSLPTPPT\
                                                                                                              REPKKVAVVR\
                                                                                                              TPPKSPSSAK\
                                                                                                              SRLQTAPVPM\
                                                                                                              PDLKNVKSKI\
                                                                                                              GSTENLKHQP\
                                                                                                              GGGKVQIINK\
                                                                                                              KLDLSNVQSK\
                                                                                                              AGSKDNIKHV\
                                                                                                              PGGGSVQIVY\
                                                                                                              KPVDLSKVTS\
                                                                                                              KAGSLGNIHH\
                                                                                                              KPGGGQVEVK\
                                                                                                              SEKLDFKDRV\
                                                                                                              QSKIGSLDNI\
                                                                                                              THVPGGGNKK\
                                                                                                              IETHKLTFRE\
                                                                                                              NAKAKTDHGA\
                                                                                                              EIVYKSPVVS\
                                                                                                              GDTSPRHLSN\
                                                                                                              VSSTGSIDMV\
                                                                                                              DSPQLATLAD\
                                                                                                              EVSASLAKQG L

  recombinant protein       Cys-Tau (2A)                    Produced by Diamond lab     N/A                   MAEPRQEFEV\
                                                                                                              MEDHACGTYGL\
                                                                                                              GDRKDQGGYT\
                                                                                                              MHQDQEGDTD\
                                                                                                              AGLKESPLQT\
                                                                                                              PTEDGSEEPG\
                                                                                                              SETSDAKSTP\
                                                                                                              TAEDVTAPLV\
                                                                                                              DEGAPGKQAA\
                                                                                                              AQPHTEIPEG\
                                                                                                              TTAEEAGIGD\
                                                                                                              TPSLEDEAAG\
                                                                                                              HVTQARMVSK\
                                                                                                              SKDGTGSDDK\
                                                                                                              KAKGADGKTK\
                                                                                                              IATPRGAAPP\
                                                                                                              GQKGQANATR\
                                                                                                              IPAKTPPAPK\
                                                                                                              TPPSSGEPPK\
                                                                                                              SGDRSGYSSP\
                                                                                                              GSPGTPGSRS\
                                                                                                              RTPSLPTPPT\
                                                                                                              REPKKVAVVR\
                                                                                                              TPPKSPSSAK\
                                                                                                              SRLQTAPVPM\
                                                                                                              PDLKNVKSKI\
                                                                                                              GSTENLKHQP\
                                                                                                              GGGKVQIINK\
                                                                                                              KLDLSNVQSK\
                                                                                                              AGSKDNIKHV\
                                                                                                              PGGGSVQIVY\
                                                                                                              KPVDLSKVTS\
                                                                                                              KAGSLGNIHH\
                                                                                                              KPGGGQVEVK\
                                                                                                              SEKLDFKDRV\
                                                                                                              QSKIGSLDNI\
                                                                                                              THVPGGGNKK\
                                                                                                              IETHKLTFRE\
                                                                                                              NAKAKTDHGA\
                                                                                                              EIVYKSPVVS\
                                                                                                              GDTSPRHLSN\
                                                                                                              VSSTGSIDMV\
                                                                                                              DSPQLATLAD\
                                                                                                              EVSASLAKQG L

  commercial assay or kit   micro BCA Protein Assay Kit     Thermo Scientific           23235                 

  chemical compound         Heparin sodium salt from\       Sigma                       H4784                 
                            porcine intestinal mucosa                                                         
  ------------------------------------------------------------------------------------------------------------------------------------

Tau expression, purification, fibrillization, and labeling {#s4-1}
----------------------------------------------------------

We utilized several forms of recombinant tau. Full-length (FL), wild-type (WT) tau contains two cysteines that create disulfide bridges and could complicate isolation of monomer. Thus in addition to preparing FL WT tau (2N4R) as previously described ([@bib10]), we purified FL tau (2N4R) that contains two cysteine/alanine substitutions (C291A, C322A), termed tau (2A). We used the 2A and WT forms of tau in our initial studies, before exclusively studying WT. Additionally, for fluorescence correlation spectroscopy (FCS), we engineered a single cysteine at the amino terminus (Cys-Tau (2A)) for labeling via maleimide chemistry. These modified proteins have fibrillization and seeding properties similar to FL WT tau. To initiate fibrillization, we incubated 8 µM tau in 10 mM HEPES, 100 mM NaCl, and 8 µM heparin (1:1 ratio of FL tau to heparin) at 37°C for 72 hr without agitation. For cysteine labeling, we incubated 200 µL of 8 µM fibrils (monomer equivalent) and monomer with 0.025 mg of Alexa Fluor-488 (AF488) C5-maleimide (Invitrogen) and 80 µM Tetramethylrhodamine-5-maleimide (Sigma-Aldrich) overnight at 4°C with gentle rotation. We quenched excess dye with 10 mM DTT for 1 hr at room temperature. For limited heparin exposure, recombinant tau at 1 µM was incubated with heparin at 1 µM for 15 min, 1 hr and 4 hr at 37°C before purification of monomer via Superdex 200 column.

We employ the following terminology:

**M~i~**: This refers to 'inert' tau monomer, whether recombinant or derived from control brain.

**M~s~**: This refers to 'seed competent' monomer, whether derived from sonicated fibrils, heparin-treated monomer, or AD brain.

Sonication and size exclusion chromatography (SEC) {#s4-2}
--------------------------------------------------

We sonicated labeled and non-labeled fibrils using a Q700 Sonicator (QSonica) at a power of 100--110 watt (Amplitude 50) at 4°C for 3 hr. Samples were then centrifuged at 10,000 x g for 10 min and 1 mL of supernatant was loaded into a Superdex 200 Increase 10/300 GL column (GE Healthcare) and eluted in PBS buffer at 4°C. After measuring the protein content of each fraction with a Micro BCA assay (Thermo Scientific, Waltham MA) and/or fluorescence using a plate reader (Tecan M1000), we aliquoted and stored samples at −80°C or immediately used them in biochemical studies and cell seeding assays. Each aliquot was thawed immediately before use. The molecular weight/radius of proteins in each fraction was estimated by running gel filtration standards (Bio-Rad): Thyroglobulin (bovine) 670 kDa/8.5 nm; γ-globulin (bovine) 158 kDa/5.29 nm; Ovalbumin (chicken) 44 kDa/3.05 nm; myoglobin (horse) 17 kDa/2.04 nm; and vitamin B~12~1.35 kDa/0.85 nm. In a prior publication ([@bib27]), [Figure 1E](#fig1){ref-type="fig"}, we demonstrated through use of crosslinking with SDS-PAGE that the SEC protocol used in this work reliably purifies monomer, dimer, and trimer.

Size-cutoff filtration {#s4-3}
----------------------

Monomer, dimer and trimer fractions were passed through a 100 kDa MWCO filter (Corning) as instructed by the manufacturer (centrifuged at 15,000 x g for 15 min at 4°C). Filtered material was immediately collected and used in seeding assay along with the non-filtered samples of the same fraction at a final concentration of 100 nM, or analyzed by limited proteolysis. Protein concentration was determined before and after filtration by determining absorption at 205 nm.

CD spectroscopy {#s4-4}
---------------

Circular dichroism (CD) measurements were performed at 25°C on a Jasco J-815 spectropolarimeter using a 0.1 cm optical path length. 200 μL of 2 μM ~Ms~ or M~i~ monomer was dialyzed onto 10 mM NaP and the spectra were measured at 0.10 nm intervals, with a band width of 1.0 nm, and scan speed of 10 nm/min. The spectrum represents the average of 4 scans in the range of 195 to 250 nm.

Enzyme-linked immunosorbent assay {#s4-5}
---------------------------------

A total tau 'sandwich' ELISA was performed similarly to that described previously ([@bib1]). Antibodies were kindly provided by Dr. Peter Davies (Albert Einstein College of Medicine). 96-well round-bottom plates (Corning) were coated for 48 hr at 4°C with DA-31 (aa 150--190) diluted in sodium bicarbonate buffer (6 µg/mL). Plates were rinsed with PBS three times, blocked for 2 hr at room temperature with Starting Block (Pierce), and rinsed with PBS five additional times. SEC fractions were diluted in SuperBlock solution (Pierce; 20% SuperBlock, diluted in TBS), and 50 µL sample was added per well. DA-9 (aa 102--150) was conjugated to HRP using the Lighting-Link HRP Conjugation Kit (Innova Biosciences), diluted 1:50 in SuperBlock solution, and 50 µL was added per well (15 µg/mL). Sample +detection antibody complexes were incubated overnight at 4°C. Plates were washed with PBS nine times with a 15 s incubation between each wash, and 75 µL 1-Step Ultra TMB Substrate Solution (Pierce) was added. Plates were developed for 30 min, and the reaction quenched with 2M sulfuric acid. Absorbance was measured at 450 nm using an Epoch plate reader (BioTek). Each plate contained a standard curve, and all samples were run in triplicate.

Fluorescence correlation spectroscopy {#s4-6}
-------------------------------------

FCS measurements were conducted on a Confocal/Multiphoton Zeiss LSM780 Inverted microscope (Carl Zeiss-Evotec, Jena, Germany), using a 40X water immersion objective as previously described ([@bib4]). Fluorescently labeled tau from SEC fractions (in PBS) was excited at 488 nm and 561 nm for 30 s, recording 10 times ([@bib3]). The data analysis was performed with Origin 7.0 (OriginLab, Northampton, MA).

Liposome-mediated transduction of tau seeds {#s4-7}
-------------------------------------------

Stable cell lines were plated at a density of 35,000 cells per well in a 96-well plate. After 18 hr, at 60% confluency, cells were transduced with protein seeds. Transduction complexes were made by combining \[8.75 μL Opti-MEM (Gibco) +1.25 μL Lipofectamine 2000 (Invitrogen)\] with \[Opti-MEM + proteopathic seeds\] for a total volume of 20 μL per well. Liposome preparations were incubated at room temperature for 20 min before adding to cells. Cells were incubated with transduction complexes for 24 hr. Biosensor cells were confirmed as HEK293T by PowerPlex sequencing. Mycoplasma contamination was ruled out by PCR analysis using VenorGem (Sigma).

FRET flow cytometry {#s4-8}
-------------------

Cells were harvested with 0.05% trypsin and fixed in 2% paraformaldehyde (Electron Microscopy Services) for 10 min, then resuspended in flow cytometry buffer. The MACSQuant VYB (Miltenyi) was used to perform FRET flow cytometry. To measure CFP and FRET, cells were excited with a 405 nm laser, and fluorescence was captured with 405/50 nm and 525/50 nm filters, respectively. To measure YFP, cells were excited with a 488 nm laser and fluorescence was captured with a 525/50 nm filter. To quantify FRET, we used a gating strategy similar to that previously described ([@bib15]). The integrated FRET density (IFD), defined as the percentage of FRET-positive cells multiplied by the median fluorescence intensity of FRET-positive cells, was used for all analyses. For each experiment,\~20,000 cells were analyzed in triplicate. Analysis was performed using FlowJo v10 software (Treestar).

Tau seeding in vitro {#s4-9}
--------------------

Recombinant full length (0N4R) tau monomer was purified as previously described ([@bib28]) at 1 mg/mL in BRB80 buffer (80 mM PIPES, 1 mM MgCl2, 1 mM EGTA, pH 6.8 with 0.3M NaCl) and boiled at 100°C for 5 min with 25 mM β-mercaptoethanol. The tau protein solution was then rapidly diluted 1:5 and cooled to 20°C in PBS, pH 7.4, to a final concentration of 0.2 mg/mL of tau and 5 mM β-mercaptoethanol. This solution was supplemented with Thioflavin T (ThT) to a final concentration of 20 µM and filtered through a sterile 0.2 µm filter. Reaction sizes of 195 µL were aliquoted from the prepared protein stock and thoroughly mixed with 5 µL of each sample at 100 nM monomer equivalent, or 5 µL of buffer control. For each sample, three different technical replicates were prepared. An opaque 96-well plate was prepared with a 3 mm glass bead added to each well to increase agitation. The recombinant tau solution was added to the plate in 200 µl reaction volumes. The plate was sealed with sealing tape to prevent evaporation and incubated in the plate reader (SpectraMax M2) at 37°C. ThT fluorescence was monitored over time with excitation and emission filters set to 444 nm and 485 nm, respectively. Fluorescence readings were taken every 5 min, with agitation for 5 s before each reading.

Tau extraction from brain and characterization by SEC {#s4-10}
-----------------------------------------------------

0.5 g frontal lobe sections from AD patients at late Braak stage (VI) and age-matched controls lacking evident tau pathology were gently homogenized at 4°C in 5 mL of TBS buffer containing protease inhibitor cocktails (Roche) using a dounce homogenizer. Samples were centrifuged at 21,000 x g for 15 min at 4°C to remove cellular debris. Supernatant was partitioned into aliquots, snap frozen and stored at −80°C. Immunopurification was performed with HJ8.5 anti-tau antibody ([@bib38]) at a ratio of 1:50 (1 µg mAb per 50 µg of total protein), incubating overnight at 4°C while rotating. To each 1 mL of mAb/brain homogenate we added 200 µL of a 50% slurry protein G-agarose beads (Santa-Cruz). We washed the bead with TBS buffer before overnight incubation at 4°C. We then centrifuged the complexes at 1000 x g for 3 min and discarded the supernatant. Beads were washed with Ag/Ab Binding Buffer, pH 8.0 (Thermo Scientific) three times. Tau bound to the beads was eluted in 100 µL low pH elution buffer (Thermo Scientific), incubated at room temperature for 7 min, followed by neutralization with 10 µL Tris-base pH 8.5. This elution step was repeated once more with 50 µL elution buffer and 5 µL Tris-base pH 8.5 for a total of 165 µL. Samples were then centrifuged at 10,000 x g for 10 min, and the supernatant loaded onto a Superdex 200 Increase 10/300 GL column (GE Healthcare). SEC fractions were frozen at −80°C after evaluation of protein content by Micro BCA assay (Thermo Scientific).

To compare different extraction methods, fresh frozen frontal lobe section from an AD patient brain was suspended in TBS buffer containing protease inhibitor cocktails (Roche) at 10% w/vol in four portions. Samples were homogenized using three different devices: a dounce homogenizer, probe sonicator (Omni International), and tissue homogenizer (Power Gen 125, Fischer Scientific). We also included one more condition of homogenizing with tissue homogenizer followed by probe sonication for 10 min. Samples were centrifuged at 21,000 x g for 15 min at 4°C to remove cellular debris. Supernatant was partitioned into aliquots followed by immunopurification.

To control for release of tau M~s~ from fibrils in AD brain, a tau KO Mouse brain was divided into two halves, followed by spiking one half with recombinant fibrils and the other with fibril-derived M~s~, both at final concentration of 10 µM monomer equivalent. Each was dounce homogenized, centrifuged, immunoprecipitated with HJ8.5 anti-tau antibody, and fractionated by SEC with identical techniques as used for human brain processing. SEC fractions were then used in seeding experiments.

Analysis of heat denaturation data {#s4-11}
----------------------------------

We analyzed the IFD from measurements of temperature-dependent seeding using global fits to a proposed unimolecular heat denaturation reaction. This analysis rests on the Arrhenius equation [@bib21]:$$k_{U} = Ae^{- \frac{E}{RT}}$$where *k~U~* is the unfolding rate constant, *E* is the activation energy, *R* is the gas constant, *T* is the temperature, and *A* is the pre-exponential factor. For the unimodal model, the data were fit globally to:$$IFD\left( t \right) = 100e^{- t/\tau}$$

Here, *t* is the heat denaturation time and *τ* = 1/*k~U~* is the unfolding time. A second, multimodal model was deployed to account for discrepancies in the early time points which appeared to suggest the presence of a lag phase in denaturation. In this model, the data were fit globally to$$\begin{matrix}
{{{IFD}\left( t \right) = 100};} & {t \leq l_{t}} \\
{{{IFD}\left( t \right) = 100e^{- {({t - l_{t}})}/\tau}};} & {t > l_{t}} \\
\end{matrix}$$where $l_{t}$ is the lag time given by$$1/l_{t} = Be^{- \frac{E}{RT}}$$and *B* is a pre-exponential factor. We used the Akaike information criterion (AIC) to evaluate the best model as it quantifies the trade-off between goodness of fit and the complexity of the model ([@bib35]). For least squares model fitting, AIC can be reduced to:$$AIC = 2p + nln\left( RSS/n \right)$$where *p* is the number of parameters in the model, *n* is the number of observations, and RSS is the residual sum of squares. The preferred model is the one with the minimum AIC. Here, we find AIC = 123 for the unimodal model and AIC = 105 for the multimodal model, which suggests the multimodal model is a better description of the denaturation data.

Crosslinking, sample processing and LC-MS/MS analysis {#s4-12}
-----------------------------------------------------

M~i~ and M~s~ tau samples were prepared as described above. In all cases, tau preparations were crosslinked at a total protein concentration of \~0.1 mg/mL using 10--20 µg starting material. The crosslinking buffer was 50 mM HEPES-KOH (pH 7.4) containing 150 mM NaCl and 1 mM DTT. The crosslinking reaction was initiated by adding disuccinimidyl suberate (DSS) stock solution (25 mM DSS-d~0~ and --d~12~, Creative Molecules) in DMF to a final concentration of 1 mM. Samples were incubated at 37°C for 1 min. For the heparin-derived M~s~ sample, heparin sulfate (Sigma) was added to a final concentration of 5 µM, followed by 1 mM DSS and the samples were incubated for 1 min at 37°C. Excess reagent was quenched by addition of ammonium hydrogen carbonate to 50 mM and incubation at 37°C for 30 min, and then flash frozen at −80°C. Absence of higher molecular species was confirmed by SDS-PAGE and coomassie stain. After the quenching step, samples were evaporated to dryness in a vacuum centrifuge and resuspended in 8M urea. Proteins were reduced with 2.5 mM TCEP (37°C, 30 min) and alkylated with 5 mM iodoacetamide (30 min, room temperature, protected from light). The sample solutions were diluted to 1M urea with 50 mM ammonium hydrogen carbonate and trypsin (Promega) was added at an enzyme-to-substrate ratio of 1:50. Proteolysis was carried out at 37°C overnight followed by acidification with formic acid to 2% (v/v). Samples were then purified by solid-phase extraction using Sep-Pak tC18 cartridges (Waters) according to standard protocols. Samples were fractionated by size exclusion chromatography (SEC) on a Superdex Peptide column as described elsewhere ([@bib25]). Two fractions collected from SEC were evaporated to dryness and reconstituted in water/acetonitrile/formic acid (95:5:0.1, v/v/v) to a final concentration of approximately 0.5 µg/µl. 2 µL each were injected for duplicate LC-MS/MS analyses on an Eksigent 1D-NanoLC-Ultra HPLC system coupled to a Thermo Orbitrap Fusion Lumos Tribrid system (Thermo Scientific). Peptides were separated on self-packed New Objective PicoFrit columns (11 cm x 0.075 mm I.D.) containing Magic C~18~ material (Michrom, 3 µm particle size, 200 Å pore size) at a flow rate of 300 nL/min using the following gradient. 0--5min = 5 %B, 5--95min = 5--35%B, 95--97 min = 35--95%B and 97--107min = 95 %B, where A = (water/acetonitrile/formic acid, 97:3:0.1) and B = (acetonitrile/water/formic acid, 97:3:0.1). The mass spectrometer was operated in data-dependent mode by selecting the five most abundant precursor ions (m/z 350--1600, charge state 3 + and above) from a preview scan and subjecting them to collision-induced dissociation (normalized collision energy = 35%, 30 ms activation). Fragment ions were detected at low resolution in the linear ion trap. Dynamic exclusion was enabled (repeat count 1, exclusion duration 30 s).

Analysis of mass spectrometry data {#s4-13}
----------------------------------

Thermo. raw files were converted into the open. mzXML format using msconvert (proteowizard.sourceforge.net) and analyzed using an in-house version of xQuest ([@bib32]). Spectral pairs with a precursor mass difference of 12.075321 Da were extracted and searched against the respective FASTA databases containing Tau (TAU_HUMAN P10636-8).xQuest settings were as follows: Maximum number of missed cleavages (excluding the crosslinking site)=2, peptide length = 5--50 aa, fixed modifications = carbamidomethyl Cys (mass shift = 57.021460 Da), mass shift of the light crosslinker = 138.068080 Da, mass shift of mono-links = 156.078644 and 155.096428 Da, MS ([@bib5]) tolerance = 10 ppm, MS ([@bib20]) tolerance = 0.2 Da for common ions and 0.3 Da for crosslink ions, search in ion-tag mode.For brain-derived samples we also included variable modifications including: Methionine oxidation = 15.99491, Ser/Thr/Tyr phosphorylation = 79.96633 and lysine ubiquitylation = 114.043 with nvariable_mod = 1. Post-search manual validation and filtering of the recombinant samples was performed using the following criteria: xQuest score \>16, mass error between −4 and +7 ppm, %TIC \>10, and a minimum peptide length of six aa. In addition, at least four assigned fragment ions (or at least three contiguous fragments) were required on each of the two peptides in a crosslink. False discovery rates (FDR) for the identified crosslinks were estimated using xprophet ([@bib32]). For the recombinant samples, M~i~ and M~s~, the FDR ranged from 6--10%. Post-search manual validation of the brain-derived samples was performed using the following criteria: xQuest score \>7, mass error between −5 and +7 ppm, %TIC \>10, and a minimum peptide length of six aa. In addition, at least four assigned fragment ions (or at least three contiguous fragments) were required on each of the two peptides in a crosslink. The FDRs for the brain samples were much higher and ranged between 20--25%. For triplicate datasets (N = 3) corresponding to the M~i~ and M~s~ boiling time course we computed consensus crosslink profiles enforcing that at least two of the three datasets contain a crosslink. Crosslink data were visualized using Xvis ([@bib13]). Average contact distance was computed by averaging the sequence separation between crosslink pairs in a given dataset. See [Figure 7---source datas 1](#fig7sdata1){ref-type="supplementary-material"} and [2](#fig7sdata2){ref-type="supplementary-material"}.

Generation of structural models using XL-MS-derived constraints {#s4-14}
---------------------------------------------------------------

High confidence crosslink pairs identified above were used to generate an ensemble of possible structures using a Rosetta protocol employing the crosslink pairs as structural restraints. The integration of XL-MS derived restraints have been previously used to refine structural models of large complexes ([@bib25]) and simpler heterodimeric complexes ([@bib19]). Based on distance distributions of crosslink pairs mapped onto crystallographic structures we set a lower bound of 15 Å and an upper bound of 25 Å for lysine Cα pairs in our simulations. Importantly, in our simulations we weighted the constraint pairs as to allow some distances above the upper bound limit. The fragment library was supplanted by using chemical shifts derived from fibrillar tau ssNMR assignments (bmrb entry 17920) using csrosetta ([@bib22]). We generated 1000 models for each of the four XL-MS datasets on a high performance cluster (biohpc.swmed.edu). Representative structures were selected according to the low Rosetta score and radius of gyration. All plots were generated with gnuplot. All figures were generated using Pymol. See [Figure 9---source data 1](#fig9sdata1){ref-type="supplementary-material"}.

Commandline used for *Ab Initio* protocol calculations with XL-MS restraints {#s4-15}
----------------------------------------------------------------------------

AbinitioRelax.default.linuxgccrelease -in:file:fasta tau.fasta -file:frag3 tau.frags3.dat -file:frag9 tau.frags9.dat -nstruct 1000 -abinitio::increase_cycles 0.5 -abinitio::relax -score::weights score13_env_hb -abinitio::rg_reweight 0.5 -abinitio::rsd_wt_helix 0.5 -abinitio::rsd_wt_loop 0.5 -disable_co_filter true -out:file:silent csrosetta.out -constraints:cst_fa_file tau.cst -constraints:cst_file tau.cst -constraints:cst_weight 0.1 -constraints:cst_fa_weight 0.1 -loopfcst::coord_cst_weight 10.0

Statistical analysis {#s4-16}
--------------------

Group mean values were analyzed by one-way ANOVA with Bonferroni post hoc significant differences test using GraphPad prism five software. Data in text and figures are represented as mean ± SD.

Replicates and sample size {#s4-17}
--------------------------

**Biological Replicates:** This refers to separately generated samples, e.g. analysis of samples from different individuals, in which the input represents a distinct biological source, or analysis of fibril preparations formed independently.

**Technical Replicates:** This refers to independently analyzed samples in which each would be expected otherwise to be identical, e.g. multiple wells in which the same cell line was treated with the same sample, or when a single brain is broken up into three fractions for identical analyses.

**Outliers:** We did not exclude outliers in any case.

**Inclusion/Exclusion of data:** In no case did we include or exclude data.

**Figure 1:** Biochemical purification of M~i~ and M~s~ and seeding into cells was carried out \~50 times over 3 years. In [Figure 1](#fig1){ref-type="fig"} the data shown is a representative dataset for M~i~ and M~s~ on SEC, seeding, microscopy and seeding following filtration. In vitro M~s~ and M~i~ aggregation was done once (using N = 3 independent technical replicates per fraction studied). Data from the titration of M~i~ and M~s~ seeding in cells is from a single representative experiment (from at least three independent studies), using technical triplicates for each sample. Primary data is available in [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}.

**Figure 2**: CD experiments were carried out with three biological replicates. A single representative experiment is shown, and the data for M~i~ and M~s~ is an average of 4 technical replicates. The FCS experiment was repeated three times with biological replicates. A single representative scan is shown. Primary data is available in [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}.

**Figure 3**: Seeding activity was measured in technical triplicates. Primary data is available in [Figure 3 source data 1](#fig3sdata1){ref-type="supplementary-material"}.

**Figure 4**: Heat denaturation was done in two biological replicates, for which a representative experiment is shown. Seeding activity was performed in technical triplicates. Primary data is available in [Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"}.

**Figure 5**: Stability of monomers and assemblies in solution was tested in a single experiment, with 32 s analyses. Primary data is available in .

**Figure 6**: This single experiment is representative of at least three distinct biological replicates. Seeding activity was determined in technical triplicates (N = 3). Primary data is available in [Figure 6---source data 1](#fig6sdata1){ref-type="supplementary-material"}.

**Figure 6---figure supplement 1**: This experiment was performed in three biological replicates. A representative gel is shown.

**Figure 7**: Each XL-MS dataset was collected in biological triplicate across the different conditions (M~i~: Recombinant; M~s~: Fibril-derived; M~s~: Heparin-derived). The figure indicates consensus crosslinks across triplicates for each condition. Primary data is available in [Figure 7---source data 1](#fig7sdata1){ref-type="supplementary-material"}, and [Figure 7---source data 2](#fig7sdata2){ref-type="supplementary-material"}.

**Figure 7---figure supplement 1**: This represents a histogram of consensus pairs across triplicates for each condition depicted in [Figure 7](#fig7){ref-type="fig"}. Primary data is available in [Figure 7---source data 1](#fig7sdata1){ref-type="supplementary-material"}, and [Figure 7---source data 2](#fig7sdata2){ref-type="supplementary-material"}.

**Figure 8**: SEC was performed at least three times, and a single representative experiment is shown. The seeding assay was performed in technical triplicate for each fraction. Spiking of tau KO brain with fibrils or M~s~ was performed once, and the SEC was performed once, with the seeding assay performed in technical triplicate. XL-MS was performed in biological triplicate for Controls vs. AD. Primary data is available in [Figure 8---source datas 1](#fig8sdata1){ref-type="supplementary-material"} and [2](#fig8sdata2){ref-type="supplementary-material"}.

**Figure 8---figure supplement 1**: XL-MS data from different methods of homogenization was performed in four individual experiments on a single biological sample. Primary data is available primary data available in .

**Figure 9**: Rosetta simulations produced models from 1000 independent trajectories across four different conditions: M~i~, M~s~, Control, AD. The pymol session is available in [Figure 9---source data 1](#fig9sdata1){ref-type="supplementary-material"}.

**Figure 9---figure supplement 1**: Plot of the energetics of the ensemble of 1000 Rosetta models built for each condition. Primary data is available in [Figure 9---source data 2](#fig9sdata2){ref-type="supplementary-material"}.

**Figure 10**: Proteolysis experiments were carried out for M~i~ and M~s~ in technical triplicate for each time point. Primary data is available in [Figure 10---source data 1](#fig10sdata1){ref-type="supplementary-material"}.

**Figure 10---figure supplement 1**: Summary data from [Figure 10](#fig10){ref-type="fig"}, comparing peptide abundance between Mi and Ms is represented as technical triplicates for each data point presented. Primary data is available in [Figure 10 source data 2](#fig10sdata2){ref-type="supplementary-material"}.

Kinetic analyses of M~i~ and M~s~ proteolysis {#s4-18}
---------------------------------------------

Limited proteolysis of M~i~ and M~s~ using trypsin was carried out in triplicate (N = 3) in 50 mM TEAB at 25°C. The enzyme to tau ratio was adjusted to 1:100 (wt/wt) with around 11 ug of M~i~/M~s~ present initially. The total reaction mixture volume was 60 µl. Aliquots were withdrawn from the reaction mixture at 1, 5, 15, 30, 60 and 120 min by using 10 µL of 10% trifluoroacetic acid (TFA) to quench the reaction (PH \<3). The trypsin-digested peptides were then desalted using an Oasis HLB plate (Waters) and eluted with 100 µL 80% acetonitrile (ACN) containing 0.1% TFA. The solvent was evaporated in a SpeedVac concentrator and the dried samples were reconstituted in 20 µl of 2% acetonitrile, 0.1% TFA and 2 µl solution was used for by LC/MS/MS analysis, the analysis were performed on an Orbitrap Elite mass spectrometer (Thermo Electron) coupled to an Ultimate 3000 RSLC-Nano liquid chromatography systems (Dionex). Samples were injected onto a 75 µm i.d., 15 cm long EasySpray column (Thermo Scientific), and eluted with a gradient from 1 to 28% buffer B over 60 min. Buffer A contained 2% (v/v) ACN and 0.1% formic acid in water, and buffer B contained 80% (v/v) ACN, 10% (v/v) trifluoroethanol, and 0.1% formic acid in water. The mass spectrometer operated in positive ion mode with a source voltage of 2.8kV and an ion transfer tube temperature of 275°C. MS scans were acquired at 240,000 resolution in the Orbitrap and up to 14 MS/MS spectra were obtained in the ion trap for each full spectrum acquired using collision-induced dissociation (CID), with charge one ions rejected. Dynamic exclusion was set for 15 s after an ion was selected for fragmentation. Raw MS data files were searched against the appropriate protein database from Uniprot, and reversed decoy sequences appended ([@bib6]) by using Protein Discovery 2.2 (Thermo Fisher Scientific). Fragment and precursor tolerances of 20ppm and 0.6 Da were specified, and 12 missed cleavages were allowed. Carbamidomethylation of Cys was set as a fixed modification and oxidation of Met was set as a variable modification. Label-free quantitation of proteins across samples was performed. Average peptide intensity values were computed for all time points for each peptide across triplicates (N = 3). To estimate differences in kinetic profiles we calculated the median value of each profile and compared the M~i~ to M~s~ ratio. See [Figure 10---source datas 1](#fig10sdata1){ref-type="supplementary-material"} and [2](#fig10sdata2){ref-type="supplementary-material"}.

Funding Information
===================

This paper was supported by the following grants:

-   http://dx.doi.org/10.13039/100000002National Institutes of Health R01NS089932 to Rohit V Pappu, Marc I Diamond.

-   Effie Marie Cain Endowed Scholarship to Lukasz A Joachimiak.

-   http://dx.doi.org/10.13039/100000002National Institutes of Health R01AG048678 to Marc I Diamond.

-   Rainwater Charitable Foundation to Marc I Diamond.

We thank Peter Davies for generously providing antibody reagents and ELISA protocol guidance. This work was supported by grants from the Tau Consortium and NIH grants awarded to 1R01NS071835 (MID), R01NS089932 (RVP and MID), and the Effie Marie Cain Endowed Scholarship (LAJ). We appreciate the help of the Live Cell Imaging Core Facility administered by Katherine Luby-Phelps, Ph.D., and the Proteomics Core Facility at the University of Texas Southwestern Medical Center. We thank Hilal Lashuel, Ph.D. for critical comments on the manuscript.

Additional information {#s5}
======================

No competing interests declared.

Conceptualization, Resources, Supervision, Writing---original draft, Writing---review and editing.

Conceptualization, Data curation, Formal analysis, Supervision, Investigation, Methodology, Writing---original draft.

Formal analysis, Investigation, Methodology.

Formal analysis, Investigation, Methodology.

Formal analysis, Investigation, Methodology.

Formal analysis, Investigation, Methodology.

Data curation, Formal analysis, Investigation, Methodology.

Investigation, Methodology, Writing---original draft.

Resources, Formal analysis, Investigation, Methodology.

Resources, Data curation, Formal analysis, Supervision, Investigation, Methodology, Writing---original draft, Project administration.

Data curation, Formal analysis, Supervision, Methodology, Writing---original draft, Project administration, Writing---review and editing.

Formal Analysis.

Additional files {#s6}
================

10.7554/eLife.36584.032

Data availability {#s7}
-----------------

All data generated or analysed during this study are included in the manuscript and supporting files.

10.7554/eLife.36584.034

Decision letter

Akhmanova

Anna

Reviewing Editor

Utrecht University

Netherlands

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

\[Editors' note: a previous version of this study was rejected after peer review, but the authors submitted for reconsideration. The first decision letter after peer review is shown below.\]

Thank you for submitting your work entitled \"Inert and seed-competent tau monomers elucidate the structural origins of aggregation\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Senior/Reviewing Editor. The reviewers have opted to remain anonymous.

Our decision has been reached after consultation between the reviewers. Based on these discussions and the individual reviews below, we regret to inform you that your work will not be considered further for publication in *eLife*.

The reviewers raised major concerns over the principal finding that a form of heat-stable tau monomer possesses seeding activity. In this case, it seems that generating adequate controls could take longer than 2-3 months, and the outcome of such experiments seems uncertain. Furthermore, the secondary finding of constraints for monomer seed structure also requires major revisions or might even need to be removed as pointed out by reviewer 1. For these reasons, we cannot proceed with your paper. However, if you were able to gather the data needed to fully support your hypothesis, we will be prepared to give this study another round of consideration and to send it to the same reviewers.

Reviewer \#1:

1\) In this paper, the authors claim to have identified two distinct monomeric forms of tau, where one form is seed-competent and the other is inert. Somehow, the seed-competent monomer can be heated to 95°C for 3 hours and still be conformationally distinct from the inert monomer. This is an extraordinary claim that will need extraordinary evidence to support it. What kind of intra-molecular interactions would resist this type of treatment? Especially, given that tau is disordered to start with. What if there were contaminating filamentous tau species (for example, formed from self-assembly due to prolonged storage and/or freeze-thaw)? Such filaments may have a far greater seed-competency than the monomer, dimer and trimer fractions tested and, therefore, even a very small amount of contamination could have a big effect. This might form a much simpler explanation of the presented results. For this reason, it would be important to know how the seeding activities of the M~s~ fraction and AD-derived tau monomer compared to the total pool of molecular tau species and to tau filaments alone. The majority of published work on seeded tau aggregation has been conducted using filamentous tau seeds and it would, therefore, be very useful to have this direct comparison presented here. At present, the authors only test the effects of contamination by dimers and trimers of tau.

2\) Also, the in vitro experiments all start with heparin-induced filament formation. These are then sonicated, centrifuged and put over a SEC column to obtain the seed-competent monomer. Yet, the authors in multiple places (including the title) state that they have elucidated the structural \'origins\' of tau aggregation. This claim is not supported by the data: the data work backwards from filaments to monomers, which is not necessarily the same as starting from some \'aggregation origin\' to form filaments. In this context, the authors\' claim that the use of a dounce homogenizer would prevent the liberation of tau monomers from filaments during brain homogenization is also important. I am not convinced this is actually the case. Neurofibrillary tangles are very large, filling most of the somato-dendritic compartment, and are likely broken up by a dounce homogenizer. The authors should directly test this before concluding that AD brain-derived seed-competent tau monomers are not actually derived from tau filaments. The centrifugation steps used prior to size exclusion chromatography (10,000 xg, 10 min, for recombinant protein and 21,000 xg, 15 min, for brain homogenates) would pellet the majority of filamentous tau aggregates and tangles, thereby excluding them from comparisons.

3\) The authors present cross-link mass-spectrometry data to study the conformation of the seed-competent and inert monomers. These experiments lead to the identification of a few distance restraints between different regions of the protein (Figure 7), which are then used to model the conformations using ROSETTA (Figure 8). It is outrageous to assume one can get anywhere near reliable 3D atomic models from such little data (the authors even describe differences in the accessibility of 2 hexapeptides inside this \~400-residue long protein!). The XL-MS data may be valuable, but Figure 8 and the corresponding section \"Models of...\" in the Results should be removed in a revised version of the paper. One prediction from Figure 4 would be that the red cross-link in Figure 7D and F would persist if samples were first incubated for 3 hours at 95^o^C. In the context of necessary extraordinary evidence, the authors should include this experiment in a revised version of the manuscript.

Reviewer \#2:

This paper provides evidence for a provocative hypothesis, that tau monomer with the VQIINK and VQIVYK sequences exposed in a consistent conformational ensemble is one of the seeds for initiating Tau aggregation.

While the data in this paper are generally supportive of this hypothesis, this paper was very hard to read/review critically as the authors forced the reviewers to go back to already published papers to get all the details-this paper has to be self-contained if I am to review the revised version.

Since M~s~ self-assembles efficiently under conditions where seeding is being assessed in the cell reporter line (heparin and Lipofectamine), how can the authors be confident that the monomer is doing the seeding and not a self-assembled M~s~? This needs to be explicitly addressed and the conditions for the cell reported seeding experiments need to be discussed in detail.

Has the heparin + Lipofectamine only control been done in the cell reporter line? I am sorry if I missed this.

It seems important to have heavy and light Tau 50:50 in the crosslinking experiment to be certain that oligomeric crosslinks are not contributing.

This paper seems to be an important contribution, and I hope the authors can revise the paper not assuming the readers have read all their papers, while integrating the control results or discussing them if they have been done.

Reviewer \#3:

This article characterizes the structural requirements for tau seeding activity. The approach is innovative, in that the identification of seeding activity follows physical characterization rather than kinetic analysis. The results are novel, in that they identify a monomeric form of full-length tau as having seeding activity. The work also is relevant for tauopathic disease, as it integrates analysis of brain tissue derived tau in the analysis. Despite these strengths, a weakness of the work is that it relies solely on hydrodynamic analysis to deduce tau structure, which depends on molecular shape as well as size. As a result, conclusions regarding the size of tau seeds seem premature and incomplete. Specifically, there is risk that the monomeric seeding activity identified by authors reflects break down of tau into aggregation-prone fragments.

1\) Figure 1 shows size exclusion chromatograms for globular protein standards and for various tau species. Leaving aside for a moment that SEC should be calibrated in terms of hydrodynamic radius rather than MW, it is worrying that M~i~ tau elutes with ovalbumin, a globular protein of similar MW but a much smaller hydrodynamic radius (half!) than 2N4R tau protein (PMID: 14769047, 15823045, 19226187, et al.). Since M~i~ is a gel-filtered form of M~r~, this result could be a sign of proteolysis, which can generate small monomeric fragments having greater aggregation propensity and possibly seeding activity. Proteolysis is always a concern when working with tau protein, but especially for M~s~ because it is generated by extensively incubation/sonication at elevated temperatures. Authors should provide SDS-PAGE or M~S~ data on M~h~, M~i~, M~r~, and M~s~ so as to disclose to what extent these preparations are proteolyzed. Because the seeding assays are sensitive, generation of even minor amounts of aggregation-competent fragments could yield a positive and confounding seeding result.

2\) Since SEC is sensitive to shape as well as size, it is inappropriate to interpret eluted tau species only in terms of size. FCS depends on shape and size too, so it does not provide a \"second opinion\". The seed depletion and spiking experiments (Figure 3) don\'t control for this problem either.

3\) It seems that M~r~ should be treated the same as M~s~, i.e. incubated and then sonicated, if it is to yield an M~i~ that can act as a control for M~s~.

4\) The legend to Figure 1D states that \"Seeding activity of each fraction was evaluated by SEC\". The meaning of this statement is not clear.

5\) The seeding assay used 0N4R tau, whereas M~i~ and M~s~ seeds were prepared from 2N4R tau. Why was this done?

6\) In the recently reported structure of tau fibrils (PMID: 28678775), the segment VQIVYK interacts with 373THKLTF378. Can authors comment on solvent exposure of THKLTF in their models?

\[Editors' note: what now follows is the decision letter after the authors submitted for further consideration.\]

Thank you for resubmitting your work entitled \"Inert and seed-competent tau monomers suggest structural origins of aggregation\" for further consideration at *eLife*. Your revised article has been favorably evaluated by Anna Akhmanova as the Senior/Reviewing Editor, and three reviewers.

The major issues raised by the reviewers have been addressed in revision. Although there was some remaining skepticism about monomeric Tau as the seed, this paper merits publication. Undoubtedly, this hypothesis will generate a lot of interest and catalyze further experimentation to scrutinize this concept. This is good for the field, because if this paper ultimately stands the test of time, it will change how we think about tauopathies.
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Author response

\[Editors' note: the author responses to the first round of peer review follow.\]

> Reviewer \#1:
>
> 1\) In this paper, the authors claim to have identified two distinct monomeric forms of tau, where one form is seed-competent and the other is inert. Somehow, the seed-competent monomer can be heated to 95°C for 3 hours and still be conformationally distinct from the inert monomer. This is an extraordinary claim that will need extraordinary evidence to support it. What kind of intra-molecular interactions would resist this type of treatment? Especially, given that tau is disordered to start with.

We were indeed initially as surprised as the reviewer to see the results of these tests, which imply strong, but not unheard-of, protein stability. Indeed, prion infectivity is well known to be resistant to boiling and autoclaving. We thus used XL-MS to test for structural changes over time at 95°C. In Figure 7 we have now studied two forms of seed-competent monomer (fibril-derived, and heparin-derived), tracking the persistence of the critical crosslinks over time. We observe that this crosslink tracks with seeding activity, being detectable at 3h, but gone by 24h of heating at 95°C. We also note (in unpublished data) that 8M urea treatment completely abolishes secondary structure detected by XL-MS, as would be predicted.

One of the major points of this paper is to challenge the notion that tau being "disordered" is synonymous with "unstructured." Our data are consistent with it being a protein that adopts multiple, stable conformational ensembles, even as a monomer in solution. In support of this general notion, we were excited to read a recent publication from the Tanaka laboratory which reports that, as we have observed for tau, Sup35 monomer (another "intrinsically disordered" prion protein) exhibits signs of discrete local structures that trigger it to form distinct strains (Ohhashi et al., 2018).

> What if there were contaminating filamentous tau species (for example, formed from self-assembly due to prolonged storage and/or freeze-thaw)? Such filaments may have a far greater seed-competency than the monomer, dimer and trimer fractions tested and, therefore, even a very small amount of contamination could have a big effect. This might form a much simpler explanation of the presented results.

This is an excellent hypothesis that we have excluded by multiple controls:

a\) In all cases except those specified to involve a freeze-thaw, we immediately took monomer preps from the SEC column to transduce cells. There was no prolonged storage of frozen material.

b\) In Figure 1 we now pass putative monomer through a 100kD filter prior to seeding, and find that the activity passes efficiently through the filter. By contrast, dimer is largely blocked, and trimer is almost completely blocked.

c\) In Figures 1 and 6, we directly compare seeding activity of monomer, dimer, trimer, and fibrillar species in dose responses. Seeding activity per nM of material is actually very similar across assembly sizes, which argues for a proportional increase in seeding activity for fibrils per molecule (i.e. assemblies are more efficient than monomer). But for dimers and trimers (most likely to contaminate the SEC preps) to see artifactual seeding activity would require enormous contamination.

d\) In Figure 3, within the limits of detection, the SEC column perfectly excludes larger species from the monomer fraction.

e)The SEC column is loaded with forms of tau that are soluble after a 10,000 x g spin, excluding large fibrils.

> For this reason, it would be important to know how the seeding activities of the M~s~ fraction and AD-derived tau monomer compared to the total pool of molecular tau species and to tau filaments alone.

The seeding activity of recombinant monomer and fibrils are remarkably similar. Please see experiments cited in Figure 6. We did not directly compare recombinant M~s~ prepared in vitro with AD-derived M~s~, however we have noted that they have relatively similar seeding efficiencies in multiple experiments.

> The majority of published work on seeded tau aggregation has been conducted using filamentous tau seeds and it would, therefore, be very useful to have this direct comparison presented here. At present, the authors only test the effects of contamination by dimers and trimers of tau.

Based on our second response to reviewer \#1, we contend that it is essentially impossible that filamentous tau is significantly contaminating our preparations. In Figure 6C we have now directly compared the seeding efficiency between monomer and fibrils (sonicated and unsonicated). We also refer the reviewer to Figure 8D. In this experiment we spiked tau KO mouse brain with recombinant fibrils or M~s~, and carried out our standard purification with SEC. In this case, we isolated minimal signal from fibril-spiked brain in the \~20-mer fraction, but no signal in the monomer fraction. By contrast, after spiking the brain preparation with M~s~ we recovered robust monomer signal. It is thus highly unlikely that fibrils are contaminating our preparations.

> 2\) Also, the in vitro experiments all start with heparin-induced filament formation. These are then sonicated, centrifuged and put over a SEC column to obtain the seed-competent monomer. Yet, the authors in multiple places (including the title) state that they have elucidated the structural \'origins\' of tau aggregation. This claim is not supported by the data: the data work backwards from filaments to monomers, which is not necessarily the same as starting from some \'aggregation origin\' to form filaments.

The reviewer is correct to point out that inferring "origins" of aggregation solely based on species fragmented from fibrils would be fraught. However, in addition to this approach (which is only how we first approached the question), we have also studied tau monomer that is converted by heparin exposure from an inert to seed-competent form, and have also isolated and studied brain-derived tau monomer. In Figure 6A we use brief exposure to heparin (prior to any larger assemblies forming) to create seed-competent monomer. Please note in Figure 6A that at 15 minutes the seeding activity purifies predominantly in the monomer fraction, and not larger assemblies. Thus, there is essentially no chance that the heparin-induced monomer we isolate was previously part of a larger assembly. Second, in Figure 8 we purify tau monomer from AD brain (controlling for possible liberation of tau monomer from fibrils (Figure 8D). This AD-derived monomer (but not control brain monomer) has intrinsic properties of self-assembly and seeding. Since (in the absence of heparin) we do not have "catalytic" control of tau monomer's conformational change in vitro, to the best of our ability we have attempted to isolate a seed-competent monomer that was not previously part of a fibril. We thus feel justified in referring to structural "origins" of aggregation as we study this monomer in comparison to an inert form. However, we defer to the editor with regard to this disagreement in terminology.

> In this context, the authors\' claim that the use of a dounce homogenizer would prevent the liberation of tau monomers from filaments during brain homogenization is also important. I am not convinced this is actually the case.

We took very seriously this critique, and thus included a new control, described in Figure 8D of spiking mouse tau KO brain either with fibrils or M~s~ prior to dounce homogenization. There is no detectable liberation of tau monomer from fibrils following dounce homogenization.

> Neurofibrillary tangles are very large, filling most of the somato-dendritic compartment, and are likely broken up by a dounce homogenizer. The authors should directly test this before concluding that AD brain-derived seed-competent tau monomers are not actually derived from tau filaments. The centrifugation steps used prior to size exclusion chromatography (10,000 xg, 10 min, for recombinant protein and 21,000 xg, 15 min, for brain homogenates) would pellet the majority of filamentous tau aggregates and tangles, thereby excluding them from comparisons.

We agree and are perhaps misunderstanding the point of this comment. As we are attempting here to define the smallest unit of seeding activity, this seems to be an appropriate step in the preparation of material.

> 3\) The authors present cross-link mass-spectrometry data to study the conformation of the seed-competent and inert monomers. These experiments lead to the identification of a few distance restraints between different regions of the protein (Figure 7), which are then used to model the conformations using ROSETTA (Figure 8). It is outrageous to assume one can get anywhere near reliable 3D atomic models from such little data (the authors even describe differences in the accessibility of 2 hexapeptides inside this \~400-residue long protein!).

First, we thank the reviewer for pointing out a certain absurdity in attributing any structure to the extreme N- and C-termini of tau. Although we never attempted to imply 3D structural knowledge of tau based on XL-MS, we have now studiously avoided any reference to "structure" as it would be implied by NMR, cryo-EM, or crystallography. Instead, we have attempted to make very clear that XL-MS provides restraints for a "structural model." Furthermore, we have now conscientiously avoided any reference to global tau structure, and have focused only on putative hairpin regions in the repeat domain. Based on the fragment libraries employed in our ROSETTA simulation there is a propensity to form secondary structure surrounding the two amyloid cores, VQIVYK and VQIINK, which leads to a diversity of models that contain hairpin-like structures within the RD1/RD2 or RD2/DR3 interface. When the seed-competent crosslinks to the RD2 region are used in the simulation we shift the equilibrium away from hairpin conformations at these sites, more so in RD1/RD2 than in RD2/RD3. Furthermore, we have limited any interpretation of XL-MS to regions in which multiple consensus crosslinks to RD2 exist. This allows us to build a model that is in fact fairly testable (and which we are pursuing in ongoing work). To this end, in Figure 10 we have now added limited proteolysis data that is consistent with our model. We hope we have made clear in the Results and Discussion that actual atomic-level resolution will require different types of studies. XL-MS and the model it supports provide a starting point with which to investigate actual structures in tau that allow it to self-assemble and act as a seed. In our reference to a "structural model" we are only intending to leave the reader with an intriguing and plausible hypothesis for our findings.

> The XL-MS data may be valuable, but Figure 8 and the corresponding section \"Models of...\" in the Results should be removed in a revised version of the paper. One prediction from Figure 4 would be that the red cross-link in Figure 7D and F would persist if samples were first incubated for 3 hours at 95^o^C. In the context of necessary extraordinary evidence, the authors should include this experiment in a revised version of the manuscript.

Based on this excellent suggestion we have now included this data in a new Figure 7. We hope the reviewer is satisfied with the qualifications we have put on the interpretations of our XL-MS results, and don't believe that proposing a very limited, local structural model based on ROSETTA is too bold.

> Reviewer \#2:
>
> This paper provides evidence for a provocative hypothesis, that tau monomer with the VQIINK and VQIVYK sequences exposed in a consistent conformational ensemble is one of the seeds for initiating Tau aggregation.
>
> While the data in this paper are generally supportive of this hypothesis, this paper was very hard to read/review critically as the authors forced the reviewers to go back to already published papers to get all the details-this paper has to be self-contained if I am to review the revised version.

We have attempted to elucidate all methods used in this version.

> Since M~s~ self-assembles efficiently under conditions where seeding is being assessed in the cell reporter line (heparin and Lipofectamine), how can the authors be confident that the monomer is doing the seeding and not a self-assembled M~s~? This needs to be explicitly addressed and the conditions for the cell reported seeding experiments need to be discussed in detail.

This is indeed a difficult question. The reviewer correctly points out that it is impossible to know what exactly happens within cells. We believe the data in Figure 5 and 8, however, are important. In these cases, we observe that monomer assembles quickly to form larger seed-competent assemblies (especially in the case of AD-derived monomer), while the larger assemblies themselves (dimer, trimer) will not self-associate. We are not certain how further to discuss the cell seeding experiments, other than to describe our methods, which we hope now are quite clear, and have been extensively reported in prior publications.

> Has the heparin + Lipofectamine only control been done in the cell reporter line? I am sorry if I missed this.

Every experiment includes Lipofectamine-treated buffer alone as a control. In experiments summarized in Figure 6 we also "transfected" cells with heparin alone and measured seeding. There was no effect, and we have alluded to this in the figure legend. We didn't see the need to include completely negative data for this, but can include it if desired. Please note also that we see seeding activity from AD-derived monomer that has never had exposure to heparin.

> It seems important to have heavy and light Tau 50:50 in the crosslinking experiment to be certain that oligomeric crosslinks are not contributing.

In the XL-MS experiments we used multiple controls to rule out multimers. Please note Figure 6---figure supplement 1, in which we display an example of a gel in which we have studied cross-linked heparin-induced M~s~, and find no evidence of multimerization. Critically, as part of our experimental protocol in every case when crosslinking monomer we run a control gel to rule out higher-order species (dimers, etc.). Additionally, when we probed the structures of M~i~ and M~s~ using limited proteolysis we passed the two forms of tau through a 100kD filter immediately prior to trypsin exposure, thus excluding multimers.

> Reviewer \#3:
>
> \[...\] A weakness of the work is that it relies solely on hydrodynamic analysis to deduce tau structure, which depends on molecular shape as well as size. As a result, conclusions regarding the size of tau seeds seem premature and incomplete. Specifically, there is risk that the monomeric seeding activity identified by authors reflects break down of tau into aggregation-prone fragments.

In this manuscript we have indeed used hydrodynamic analyses to infer sizes of assemblies, resolving those that are monomer from dimers, trimers, etc. We make no claims about the precise hydrodynamic radii. Additionally, in the current resubmission, we use other methods to infer monomer structure (e.g. double-label fluorescence correlation spectroscopy, 100kD filter cutoffs, and molecular crosslinking to confirm monomer structure). In responses below we address the question of seed-competent tau fragments in more detail.

> 1\) Figure 1 shows size exclusion chromatograms for globular protein standards and for various tau species. Leaving aside for a moment that SEC should be calibrated in terms of hydrodynamic radius rather than MW, it is worrying that M~i~ tau elutes with ovalbumin, a globular protein of similar MW but a much smaller hydrodynamic radius (half!) than 2N4R tau protein (PMID: 14769047, 15823045, 19226187, et al.).

We thank the reviewer for educating us as to an appropriate indicator for standards on SEC, and have altered our figures accordingly. We do not intend to use SEC on the Superdex 200 column as a precise marker of hydrodynamic radius or molecular size. Instead we are simply seeking to pick fractions where tau monomer is likely to be separated from larger assemblies. In choosing the fraction B5 as the source of monomer, we do so recognizing that tau monomer appears to reflect an ensemble of structures that are slightly polydisperse as they come off of the column (especially in comparison to ovalbumin, which is more monodisperse). In multiple other experiments described especially in response to reviewer \#1, we have attempted to test whether the minimal tau seed could be a multimer, and we find no evidence for this. As a final point, in our prior manuscript (Mirbaha et al., 2015), we carried out crosslinking of assemblies derived from putative monomer, dimer, and trimer fractions, and ran out the samples on a gel (Figure 1E, F, G). While we were studying tau RD, please note the fidelity of our SEC, in which we observed crosslinked assemblies that correlated with our predicted assembly sizes.

> Since M~i~ is a gel-filtered form of M~r~, this result could be a sign of proteolysis, which can generate small monomeric fragments having greater aggregation propensity and possibly seeding activity. Proteolysis is always a concern when working with tau protein, but especially for M~s~ because it is generated by extensively incubation/sonication at elevated temperatures.

While we have been concerned about proteolysis, we have found no evidence of this in the absence of sonication (which indeed can produce fragments, as in Figure 6---figure supplement 1A). First of all, we emphasize that we find seed-competent tau monomer in conditions that do not involve sonication, and which do not change tau size. For example, in the new manuscript, please see Figure 6---figure supplement 1B, in which we have taken inert and heparin-induced seed-competent monomers, crosslinked them (or not) and resolved them by SDS-PAGE. While there are several species visible (it is very difficult to have a completely pure monomer preparation), even with the over-loaded gel the reviewer will observe that there is no evidence of significantly smaller fragments or larger assemblies associated with the seeding activity. We have also carried out multiple controls to rule out multimerization, even of small fragments, as referenced in prior responses. In particular, we refer the reviewer to double-label FCS experiments in Figure 2, in which we find no evidence that multiple labels are incorporated into putative monomers, while we easily detect them in putative dimers and trimers. Furthermore, the heat denaturation steps, which we show are sufficient to dissociate oligomers, do not change the seeding activity (or elution characteristics) of the seed-competent monomer. Finally, in Figure 7C we observe that sonication has no effect on the seeding activity of otherwise inert monomer, M~i~, despite causing a minor degree of fragmentation (Figure 6---figure supplement 1A). We believe at this point the data do not support the hypothesis that we are somehow purifying tiny amounts of seed-competent, aggregated fragments that account for the activity of M~s~.

> Authors should provide SDS-PAGE or M~S~ data on M~h~, M~i~, M~r~, and M~s~ so as to disclose to what extent these preparations are proteolyzed. Because the seeding assays are sensitive, generation of even minor amounts of aggregation-competent fragments could yield a positive and confounding seeding result.

This is an excellent caveat. In response to this reviewer we performed SDS-

PAGE on sonicated monomer and observed evidence of fragmentation (Figure 6---figure supplement 1A). In Figure 6C we observe that sonication does not produce seed-competent species from M~i~. Nonetheless we additionally confirmed by other means that we were not generating aggregation-prone fragments by simply treating tau monomer (confirmed intact) with heparin, and also by isolating seed-competent monomer through gentle methods from AD brain. It seems to us to be incredibly unlikely that 15min of heparin exposure is sufficient to fragment tau to form cryptic seed-competent fragments than then spontaneously self-assemble.

> 2\) Since SEC is sensitive to shape as well as size, it is inappropriate to interpret eluted tau species only in terms of size. FCS depends on shape and size too, so it does not provide a \"second opinion\". The seed depletion and spiking experiments (Figure 3) don\'t control for this problem either.

We take the reviewer's point, and would emphasize only that control proteins elute from the SEC as rough markers of tau size. We make no specific reference to the "molecular weight" of the tau assemblies we elute from the SEC columns. Furthermore, the column we used (Superdex 200) is designed to resolve an enormous window of assembly sizes. It is not ideal to resolve ovalbumin and tau, and thus it is not surprising that these two proteins co-elute to some extent. We have predominantly been interested in resolving monomer, dimer, trimer, etc., and not attempting to determine a precise hydrodynamic radius. While FCS and SEC do use similar metrics to infer size, they are not identical (FCS does not involve interaction of protein with a column substrate), and the use of double-label FCS enables us to rule out multimeric assemblies of tau within the putative monomer fraction. Likewise, the seed depletion and spiking experiments are not done to determine size, per se, but to rule out the possibility of contamination of larger species (putative dimers and trimers) into the monomer fraction.

> 3\) It seems that M~r~ should be treated the same as M~s~, i.e. incubated and then sonicated, if it is to yield an M~i~ that can act as a control for M~s~.

As part of our revision we have directly tested whether sonication of M~i~ produces seeding activity in the absence of heparin (Figure 6C). It does not. We would also point out that we can produce M~s~ without sonication, whether by brief (15min) exposure of recombinant monomer to heparin, or by purification of monomer from AD brain.

> 4\) The legend to Figure 1D states that \"Seeding activity of each fraction was evaluated by SEC\". The meaning of this statement is not clear.

We have clarified this statement.

> 5\) The seeding assay used 0N4R tau, whereas M~i~ and M~s~ seeds were prepared from 2N4R tau. Why was this done?

This was done purely for "historical" reasons because the Colby lab uses this form of tau for their seeding assays.

> 6\) In the recently reported structure of tau fibrils (PMID: 28678775), the segment VQIVYK interacts with 373THKLTF378. Can authors comment on solvent exposure of THKLTF in their models?

The R4/R' interface (which includes the THKLTF region) according to secondary structure and modeling analysis as well as previous work is predicted to be disordered. In our models, both M~i~ and M~s~, the THKLTF region is solvent exposed and not engaged in any interactions. The published cryoEM structure of the PHFs is also not consistent with many of the previous studies using solid state NMR and other methods. The conditions under which the fibrils form and the presence of the PTMs could favor a specific conformational arrangement of a fibril. Notably, the core of the fibril mediated by RD3 and RD4 in cryoEM structure buries many charged residues, which is quite surprising as this should destabilize the contacts between VQIVYK and THKLTF. More experiments will reveal the importance of this regions role in fibrils, in particular in strains, beyond this structure of a fibril derived from a single AD patient as recently reported.
